register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01762644 | [
{
"id_field": "org_study_id",
"id_value": [
"PRL001-PB-01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2015-000105-39"
]
},
{
"id_field": "acronym",
"id_value": [
"IIT"
]
}
] | https://clinicaltrials.gov/study/NCT01762644 | The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients | The purpose of this study is to determine if the combination of oral cyclosporine, an immune therapy and oral omeprazole, a proton pump inhibitor, are effective in rendering insulin independence among recent onset type 1 diabetes patients. This two-arm study is designed to evaluate the safety and efficacy for insulin i... | A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes. | [
{
"name": "Oral Cyclosporine and Oral Omeprazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Oral Omeprazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Immune Tolerance and Proton Pump Inhibitor",
"design_group_title": "Arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Oral Cyclosporine and Ora... | [
"Type 1 Diabetes"
] | [
"Perle Bioscience, Inc."
] | [
"Syreon Corp."
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "奥美拉唑",
"lang": "CN"
},
{
"name": "Omeprazole",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IIT"
}
] |
NCT02580591 | [
{
"id_field": "org_study_id",
"id_value": [
"1245.72"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-005256-26"
]
}
] | https://clinicaltrials.gov/study/NCT02580591 | Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) | The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin | A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3) | [
{
"name": "Empagliflozin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "For blinding purposes",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Empagliflozin low dose",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "For blinding purposes",
"intervention_name": "Placebo",
"interv... | [
"Diabetes Mellitus, Type 1"
] | [
"Boehringer Ingelheim GmbH"
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "恩格列净",
"lang": "CN"
},
{
"name": "Empagliflozin",
"lang": "EN"
},
{
"name": "エンパグリフロジン",
"lang": "JP"
}
]
] | null |
NCT00791921 | [
{
"id_field": "org_study_id",
"id_value": [
"CDP870-275-08-003"
]
}
] | https://clinicaltrials.gov/study/NCT00791921 | Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA) | The objectives of this study are to verify the superiority in efficacy (American College of Rheumatology 20%: ACR20) and investigate the pharmacokinetics and safety of CDP870 versus placebo without coadministration of MTX in active RA patients in whom MTX cannot be administrated. | A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated. | [
{
"description": "400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)",
"name": "CDP870",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo given every 2 weeks until Week22 (SC)",
... | [
{
"design_group_description": "400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks",
"design_group_title": "CDP870 200mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"i... | [
"Rheumatoid Arthritis"
] | [
"Otsuka Pharmaceutical Co., Ltd."
] | [
"UCB Japan Co. Ltd."
] | [
[
{
"name": "培塞利珠单抗",
"lang": "CN"
},
{
"name": "Certolizumab Pegol",
"lang": "EN"
},
{
"name": "セルトリズマブ ペゴル（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "2aaa22922d4944e2e2a58a5333253035",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "802520225ae2a3a2833a2da592004555",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "HIK... |
NCT00354744 | [
{
"id_field": "org_study_id",
"id_value": [
"ARST0431"
]
},
{
"id_domain": "Clinical Trials.gov",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CDR0000489215"
]
},
{
"id_domain": "Children's Oncology Group",
"id_field": "seconda... | https://clinicaltrials.gov/study/NCT00354744 | High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma | RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide, etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor... | Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma | [
{
"description": "Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.<br/>Day 1 of Weeks 35, 38, 41 and 44.<br/>Given IV",
"name": "dactinomycin",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Actinomycin-D",
"Cosmegen",
... | [
{
"design_group_description": "Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophospha... | [
"Sarcoma"
] | [
"The Children's Oncology Group Foundation, Inc."
] | [
"National Cancer Institute"
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name"... | null |
NCT00217230 | [
{
"id_field": "org_study_id",
"id_value": [
"D153-P507"
]
}
] | https://clinicaltrials.gov/study/NCT00217230 | Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older | The purpose of this study is to determine the efficacy, safety and tolerability of the liquid formulation of CAIV-T against culture confirmed influenza illness in adults aged 60 years and older. In addition this study aims to demonstrate superiority of CAIV-T when compared with placebo and the effect on economic resour... | A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older CAIV-T, Liquid Formulation | [
{
"name": "CAIV-T",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
}
] | null | [
"Influenza"
] | [
"MedImmune LLC"
] | [
"Wyeth AB"
] | [
[
{
"name": "Influenza vaccine live(MedImmune LLC)",
"lang": "EN"
}
]
] | null |
NCT06497556 | [
{
"id_field": "org_study_id",
"id_value": [
"BO45217"
]
},
{
"id_domain": "EU CT Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2024-510908-37-00"
]
},
{
"id_field": "acronym",
"id_value": [
"Krascendo 1"
]
}... | https://clinicaltrials.gov/study/NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC). | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer | [
{
"description": "Divarasib will be administered orally QD",
"name": "Divarasib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Sotorasib will be administered orally QD",
"name": "Sotorasib",
"normalized_type": "3d1aa88261d64c038413723970f... | [
{
"design_group_description": "Participants will receive divarasib orally, once daily (QD).",
"design_group_title": "Divarasib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description... | [
"Non-Small Cell Lung Cancer",
"KRAS G12C Lung Cancer"
] | [
"Roche Holding AG"
] | [
"Chugai Pharmaceutical Co., Ltd."
] | [
[
{
"name": "Divarasib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Krascendo 1"
}
] |
NCT03020030 | [
{
"id_field": "org_study_id",
"id_value": [
"16-001"
]
},
{
"id_field": "secondary_id",
"id_value": [
"16-001"
]
}
] | https://clinicaltrials.gov/study/NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They ... | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | [
{
"description": "Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization",
"name": "Pegaspargase",
"normalized_ty... | [
{
"design_group_description": "Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.<br/>Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopuri... | [
"Acute Lymphoblastic Leukemia, Pediatric"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"Servier Pharmaceuticals LLC"
] | [
[
{
"name": "培门冬酶",
"lang": "CN"
},
{
"name": "Pegaspargase",
"lang": "EN"
},
{
"name": "ペグアスパルガーゼ",
"lang": "JP"
}
],
[
{
"name": "门冬酰胺酶",
"lang": "CN"
},
{
"name": "Asparaginase (Erwinia)",
"lang": "EN"
}
]
] | null |
NCT06407232 | [
{
"id_field": "org_study_id",
"id_value": [
"2024-0174"
]
},
{
"id_domain": "UW Madison",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"A561000"
]
},
{
"id_domain": "UW Madison",
"id_field": "secondary_id",
"id_type": "Other... | https://clinicaltrials.gov/study/NCT06407232 | Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months. | An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients | [
{
"description": "480 mg taken orally once daily, for 84 days",
"name": "Letermovir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Prevymis"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Enrolled participants will be converted from treatment with ganciclovir derivatives to letermovir",
"design_group_title": "Letermovir for CMV in Transplant Patients",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c... | [
"Cytomegalovirus Infections",
"Kidney Transplant Infection",
"Pancreas Transplant"
] | [
"University of Wisconsin-Madison"
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "来特莫韦",
"lang": "CN"
},
{
"name": "Letermovir",
"lang": "EN"
},
{
"name": "レテルモビル",
"lang": "JP"
}
]
] | null |
NCT00765206 | [
{
"id_field": "org_study_id",
"id_value": [
"18134"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CL2008-02"
]
},
{
"id_domain": "Merck",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"P07814"
]
}
] | https://clinicaltrials.gov/study/NCT00765206 | A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED) | Open-label randomized crossover design study. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. | Randomized, Crossover Pharmacodynamic Study Comparing the Effects of Zegerid® (20 mg Omeprazole/Sodium Bicarbonate) and Prilosec OTC® Tablets (20 Mg-equivalent Omeprazole) | [
{
"description": "Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.",
"name": "Omeprazole/sodium bicarbonate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Zegerid"
],
"type": "Drug"
},
{
"description": "Single dose of omepr... | [
{
"design_group_description": "Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule",
"design_group_title": "Zegerid",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interventio... | [
"Gastric Acid",
"Human Experimentation"
] | [
"Bayer AG"
] | [
"Bausch Health Americas, Inc."
] | [
[
{
"name": "奥美拉唑碳酸氢钠",
"lang": "CN"
},
{
"name": "Omeprazole/Sodium Bicarbonate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2389a22ee4853802a3a8a345ed49a25e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CL2008-02"
},
{
"identifier_source": [
... |
NCT05060406 | [
{
"id_field": "org_study_id",
"id_value": [
"LY06006/CT-CHN-302"
]
}
] | https://clinicaltrials.gov/study/NCT05060406 | A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture | A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture, as well as an exploratory population pharmacokinetic analysis of LY06006. | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture | [
{
"description": "60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total",
"name": "LY06006",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"recombinant human monoclonal anti-RANKL antibody injection"
],
"type": "Drug"
}
] | [
{
"design_group_description": "injection<br/>Interventions:<br/>Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D",
"design_group_title": "LY06006 60mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c... | [
"Postmenopausal Osteoporosis"
] | [
"Luye Pharma Group Ltd."
] | [
"Shandong Boan Biotechnology Co., Ltd."
] | [
[
{
"name": "地舒单抗生物类似药 (山东博安生物)",
"lang": "CN"
},
{
"name": "Denosumab Biosimilar (Boan Biological)",
"lang": "EN"
}
]
] | null |
NCT01460472 | [
{
"id_field": "org_study_id",
"id_value": [
"EC-AR-1E10 MAb-301"
]
},
{
"id_domain": "International Clinical Trials Register Platform (ICTRP), WHO",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"ISRCTN47153584"
]
}
] | https://clinicaltrials.gov/study/NCT01460472 | Immunotherapy With Racotumomab in Advanced Lung Cancer | This is a prospective, randomized, open label, parallel-group, multicenter phase III study to evaluate the efficacy and safety of active specific immunotherapy with racotumomab plus best supportive care versus best supportive care in patients with advanced NSCLC who have achieved an Objective Response (Partial or Compl... | A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer. | [
{
"description": "Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression ... | [
{
"design_group_description": "Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.",
"design_group_title": "Racotumomab plus Best Support Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized... | [
"NSCLC",
"Lung Cancer, Non-small Cell"
] | [
"Recombio SL"
] | [
"Innogene Kalbiotech Pte Ltd.",
"Eurofarma Laboratórios SA",
"Laboratorio Elea Phoenix SA",
"CIMAB SA"
] | [
[
{
"name": "Racotumomab",
"lang": "EN"
}
]
] | null |
NCT07361003 | [
{
"id_field": "org_study_id",
"id_value": [
"SIM0063-302"
]
},
{
"id_domain": "Center for drug Evaluation, NMPA",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"CTR20254831"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT07361003 | A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer | The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.<br/>The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer parti... | A Phase Ib/III Study of Suvemcitug Plus Trifluridine/Tipiracil Tablets (FTD/TPI) Versus Placebo Plus Trifluridine/Tipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer | [
{
"description": "Suvemcitug injection at 1.5mg/kg, Trifluridine/tipiracil tablets at 35 mg/m²",
"name": "Suvemcitug injection, trifluridine/tipiracil tablets",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Suvemcitug placebo injection, Trifluridi... | [
{
"design_group_description": "Participants will receive Suvemcitug injection (at 1.5mg/kg for Phase Ib; and a recommended dose level based on Phase Ib result will be used for Phase III part) on Day 1 and Day 15 of each cycle (28 days), and trifluridine/tipiracil tablets at 35 mg/m² on day 1-5, 8-12 of each cyc... | [
"Refractory Metastatic Colorectal Cancer"
] | [
"Jiangsu Simcere Pharmaceutical Co., Ltd."
] | [
"Jiangsu Simcere Pharmaceutical Co., Ltd."
] | [
[
{
"name": "曲氟尿苷替匹嘧啶",
"lang": "CN"
},
{
"name": "Tipiracil Hydrochloride/Trifluridine",
"lang": "EN"
},
{
"name": "トリフルリジン/チピラシル塩酸塩",
"lang": "JP"
}
],
[
{
"name": "苏维西塔单抗",
"lang": "CN"
},
{
"name": "Sevacizumab",
... | null |
NCT00192400 | [
{
"id_field": "org_study_id",
"id_value": [
"D153-P504"
]
}
] | https://clinicaltrials.gov/study/NCT00192400 | Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children. | The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months. | A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children | [
{
"name": "CAIV-T",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
}
] | null | [
"Healthy"
] | [
"MedImmune LLC"
] | [
"Wyeth AB"
] | [
[
{
"name": "Influenza vaccine live(MedImmune LLC)",
"lang": "EN"
}
]
] | null |
NCT03345095 | [
{
"id_field": "org_study_id",
"id_value": [
"EORTC-BTG-1709"
]
},
{
"id_field": "acronym",
"id_value": [
"MIRAGE"
]
}
] | https://clinicaltrials.gov/study/NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma | The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase I... | A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma | [
{
"description": "Intravenous administration of Marizomib",
"name": "Marizomib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral Administration of Temozolomide",
"name": "Temozolomide",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_description": "Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib",
"design_group_title": "Experimental Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Newly Diagnosed Glioblastoma"
] | [
"European Organisation for Research & Treatment of Cancer"
] | [
"Celgene Corp.",
"Canadian Cancer Trials Group"
] | [
[
{
"name": "替莫唑胺",
"lang": "CN"
},
{
"name": "Temozolomide",
"lang": "EN"
},
{
"name": "テモゾロミド",
"lang": "JP"
}
],
[
{
"name": "Marizomib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "23a258a2299e332a9a4a42ee9e0d82e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "4e395ee258e2a92233202eed2023e3ea",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "EOR... |
NCT06051409 | [
{
"id_field": "org_study_id",
"id_value": [
"HQP1351AG301"
]
}
] | https://clinicaltrials.gov/study/NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. | A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of Olverembatinib combined with chemotherapy versus Imatinib combined with chemotherapy in subjects with newly diagnosed Ph+ALL. | A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | [
{
"description": "Orally, once every other day (QOD).",
"name": "Olverembatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Orally, once daily (QD).",
"name": "Imatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type... | [
{
"design_group_description": "Olverembatinib in combination with chemotherapy",
"design_group_title": "Olverembatinib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Oral... | [
"Ph+ ALL"
] | [
"Ascentage Pharma Group, Inc."
] | [
"Healthquest Pharma Ltd."
] | [
[
{
"name": "奥雷巴替尼",
"lang": "CN"
},
{
"name": "Olverembatinib",
"lang": "EN"
}
]
] | null |
NCT00087399 | [
{
"id_field": "org_study_id",
"id_value": [
"NCCTG-N03C5"
]
},
{
"id_domain": "CTRP (Clinical Trials Reporting System)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2012-02616"
]
},
{
"id_domain": "PDQ (Physician Data Query... | https://clinicaltrials.gov/study/NCT00087399 | Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy | RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes.<br/>PURPOSE: This randomized phase... | A Phase III Randomized, Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone | [
{
"name": "gabapentin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "antidepressant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.<... | [
"Breast Cancer",
"Hot Flashes"
] | [
"Alliance Foundation Trials LLC"
] | [
"National Cancer Institute"
] | [
[
{
"name": "加巴喷丁",
"lang": "CN"
},
{
"name": "Gabapentin",
"lang": "EN"
},
{
"name": "ガバペンチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "45e2ea25ea290452952ed92a82e8258d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NCCTG N03C5"
}
] |
NCT01398072 | [
{
"id_field": "org_study_id",
"id_value": [
"11/0078"
]
}
] | https://clinicaltrials.gov/study/NCT01398072 | Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) is the cause of considerable deaths, and exacerbations (flare up of symptoms) are a major cause of hospital admission in the UK. Bacterial infections play an important role in the development of COPD, however, there is little information available about the use of long term ... | A Phase III Single-blind, Randomised Placebo Controlled Trial of Long Term Therapy in Patients With Stable COPD Using Moxifloxacin, Azithromycin and Doxycycline: a Bayesian Decision Analysis, Including Other Criteria, Will be Used to Distinguish the Optimal Antibiotic Treatment | [
{
"description": "An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.",
"name": "Moxifloxacin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "An oral dose of 250 mg once daily three times a week (every other day).",
"name":... | [
{
"design_group_title": "Moxifloxacin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.",
"i... | [
"Chronic Obstructive Pulmonary Disease (COPD)."
] | [
"University College London"
] | [
"Royal Free Hampstead NHS Trust",
"University of Cambridge"
] | [
[
{
"name": "盐酸多西环素",
"lang": "CN"
},
{
"name": "Doxycycline Hyclate",
"lang": "EN"
},
{
"name": "ドキシサイクリン塩酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "阿奇霉素",
"lang": "CN"
},
{
"name": "Azithromycin",
"lang": "EN"
},
... | null |
NCT01423032 | [
{
"id_field": "org_study_id",
"id_value": [
"WISP_RI05"
]
}
] | https://clinicaltrials.gov/study/NCT01423032 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | Bendamustine demonstrated clinical activity in pre-treated hematological malignancies due to its unique mechanism of action distinct from standard alkylating agents. This study assesses its efficacy in patients with chronic lymphocytic leukemia pre-treated with an alkylator, in comparison to fludarabine.<br/>Patients w... | Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV | [
{
"description": "100 mg/m² iv, day 1+2, q4w",
"name": "bendamustine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "25 mg/m² iv, days 1-5, q4w",
"name": "Fludarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Dr... | [
{
"design_group_title": "Bendamustine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "100 mg/m² iv, day 1+2, q4w",
"intervention_name": "bendamustine",
"interv... | [
"Chronic Lymphocytic Leukemia"
] | [
"WiSP Wissenschaftlicher Service Pharma GmbH"
] | [
"ribosepharm GmbH",
"Mundipharma Research GmbH & Co. KG",
"Klinikum Leverkusen gGmbH"
] | [
[
{
"name": "盐酸苯达莫司汀",
"lang": "CN"
},
{
"name": "Bendamustine Hydrochloride",
"lang": "EN"
},
{
"name": "ベンダムスチン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00533624 | [
{
"id_field": "org_study_id",
"id_value": [
"CERL080A-US10"
]
}
] | https://clinicaltrials.gov/study/NCT00533624 | Myfortic vs. Cellcept in Kidney Transplant Recipients | The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients. | Head to Head Comparison of Myfortic vs. Cellcept in the Treatment of Kidney Transplant Recipients Using Our Current Center Standardized Concomitant Immunosuppressive Protocol | [
{
"description": "Myfortic® 1,440 mg/day",
"name": "Mycophenolate Sodium Delayed Release Tablets",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Cellcept® 2,000 mg/day",
"name": "Mycophenolate Mofetil",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels o... | [
"End Stage Renal Disease"
] | [
"University of Miami"
] | [
"Novartis Pharmaceuticals Corp."
] | [
[
{
"name": "吗替麦考酚酯",
"lang": "CN"
},
{
"name": "Mycophenolate Mofetil",
"lang": "EN"
},
{
"name": "ミコフェノール酸 モフェチル",
"lang": "JP"
}
]
] | null |
NCT00799643 | [
{
"id_field": "org_study_id",
"id_value": [
"CHS 06-20-2"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01DK074556"
]
},
{
"id_field": "acronym",
"id_value": [
"TINSALT2D-II"
]
}
] | https://clinicaltrials.gov/study/NCT00799643 | Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II | Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sug... | Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate | [
{
"description": "Salsalate 3.5 g/d orally, divided dosing",
"name": "Salsalate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"disalsid"
],
"type": "Drug"
},
{
"name": "Salsalate Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Salsalate, 3.5 g/d orally, divided dosing",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Salsalate 3.5 g/d ... | [
"Type 2 Diabetes Mellitus"
] | [
"Joslin Diabetes Center, Inc."
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "双水杨酯",
"lang": "CN"
},
{
"name": "Salsalate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "0a5de58a39993532a54de52da3edeee5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TINSALT2D-II"
}
] |
NCT00794443 | [
{
"id_field": "org_study_id",
"id_value": [
"529-CL-028"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ONO-5920-05"
]
}
] | https://clinicaltrials.gov/study/NCT00794443 | ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients | This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation. | A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation. | [
{
"description": "Oral",
"name": "YM529 / ONO-5920",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Minodronic acid",
"ONO-5920",
"YM529"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Monthly intermittent administration, dose 1",
"design_group_title": "1. Monthly - Dose 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Ora... | [
"Osteoporosis",
"Bone Loss, Age-Related"
] | [
"Astellas Pharma, Inc."
] | [
"Ono Pharmaceutical Co., Ltd."
] | [
[
{
"name": "米诺膦酸",
"lang": "CN"
},
{
"name": "Minodronic Acid Hydrate",
"lang": "EN"
},
{
"name": "ミノドロン酸水和物",
"lang": "JP"
}
]
] | null |
NCT06607419 | [
{
"id_field": "org_study_id",
"id_value": [
"CBC-ALL2024-1"
]
},
{
"id_field": "acronym",
"id_value": [
"BBClean"
]
}
] | https://clinicaltrials.gov/study/NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia | The goal of this clinical trial is to evaluate the efficacy of Blinatumomab in pediatric patient with newly diagnosed acute B-Lymphoblastic leukemia with poor response to early chemotherapy, i.e. day 19 MRD ≥ 0.1% (low-risk) or day 19 MRD ≥ 0.01% (intermediate-risk). The main question is:<br/>• If the flow cytometric M... | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia | [
{
"description": "Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.",
"name": "Blinatumomab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients in this group should receive Blinatumomab",
"design_group_title": "Blinatumomab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Rec... | [
"B-Cell Lymphoblastic Leukemia"
] | [
"Shanghai Jiao Tong University School of Medicine"
] | [
"Ningbo Women and Children’s Hospital",
"The Third Xiangya Hospital of Central South University",
"Fujian Medical University",
"Guizhou Provincial People's Hospital",
"Wenzhou Medical College",
"Hunan Provincial People's Hospital",
"The First Affiliated Hospital of Xiamen University"
] | [
[
{
"name": "贝林妥欧单抗",
"lang": "CN"
},
{
"name": "Blinatumomab",
"lang": "EN"
},
{
"name": "ブリナツモマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BBClean"
}
] |
NCT06316830 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00000075"
]
},
{
"id_field": "acronym",
"id_value": [
"Optimal Bup"
]
}
] | https://clinicaltrials.gov/study/NCT06316830 | Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose | The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg).<br/>The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance... | Randomized Clinical Trial of a 16 mg vs. 24 mg Maintenance Daily Dose of Buprenorphine to Increase Retention in Treatment Among People With Opioid Use Disorder | [
{
"description": "Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal bupreno... | [
{
"design_group_description": "The experimental intervention is a high daily maintenance dose of buprenorphine (24 mg) plus any usual clinical care the participant receives at the clinic. This high daily dose is the upper limit of the FDA-approved dose range and was selected based on preclinical studies, clinic... | [
"Opioid Use Disorder"
] | [
"Rhode Island Hospital"
] | [
"Brown University"
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Optimal Bup"
}
] |
NCT04973306 | [
{
"id_field": "org_study_id",
"id_value": [
"B2021-369R"
]
},
{
"id_field": "acronym",
"id_value": [
"iCROSS"
]
}
] | https://clinicaltrials.gov/study/NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC | The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cI... | Neoadjuvant Immunotherapy Combined With Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (cII-III Stage): A Multi-center Prospective Randomized Clinical Trial | [
{
"description": "Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.<br/>Radiotherapy: A total radiat... | [
{
"design_group_description": "Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.",
"design_group_title": "Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody",
"design_group_type": "Experimental",... | [
"Esophageal Squamous Cell Carcinoma Stage II",
"Esophageal Squamous Cell Carcinoma Stage III"
] | [
"Zhongshan Hospital Fudan University"
] | [
"Zhongshan Hospital Fudan University",
"Shanghai Xuhui District Central Hospital",
"Zhejiang Cancer Hospital",
"Sun Yat-Sen University",
"Sichuan Cancer Hospital",
"Tianjin Medical University Cancer Institute and Hospital",
"Cancer Hospital Chinese Academy of Medical Sciences",
"The First Affiliated H... | [
[
{
"name": "替雷利珠单抗",
"lang": "CN"
},
{
"name": "Tislelizumab",
"lang": "EN"
},
{
"name": "チスレリズマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "iCROSS"
}
] |
NCT03047005 | [
{
"id_field": "org_study_id",
"id_value": [
"1506016065-M"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK049587"
]
}
] | https://clinicaltrials.gov/study/NCT03047005 | Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy | This study will test the effectiveness and relative efficacy of naltrexone/bupropion medication as a maintenance therapy for the treatment of binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bupropion medication results in sup... | Behavioral and Pharmacologic Treatment of Binge Eating and Obesity | [
{
"description": "NB medication",
"name": "NB medication (Naltrexone Bupropion combination)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Contrave"
],
"type": "Drug"
},
{
"description": "Placebo",
"name": "Placebo",
"normalized_type": "ffd65a... | [
{
"design_group_description": "Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.",
"design_group_title": "NB medication",
"design_gro... | [
"Binge-Eating Disorder",
"Obesity"
] | [
"Yale University"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "盐酸纳曲酮/盐酸安非他酮",
"lang": "CN"
},
{
"name": "Bupropion Hydrochloride/Naltrexone Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT01809132 | [
{
"id_field": "org_study_id",
"id_value": [
"U01AA021893-01"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01AA021893-01"
]
}
] | https://clinicaltrials.gov/study/NCT01809132 | Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis | This study will compare two different treatments of acute alcoholic hepatitis. The current standard of care is treatment with corticosteroids (methylprednisolone). This will be compared to treatment with anakinra, pentoxifylline, plus zinc sulfate. The participants will be treated and followed for 6 months and the two ... | Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis | [
{
"description": "Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.",
"name": "Anakinra",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Kineret"
],
"type": "Drug"
},
{
"description": "Pentoxifylline, gener... | [
{
"design_group_description": "anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days",
"design_group_title": "Anakinra & Pentoxifylline & Zinc Sulfate",
"design_group_type": "Experimental",
"design_gr... | [
"Acute Alcoholic Hepatitis"
] | [
"The University of Texas Southwestern Medical Center"
] | [
"University of Massachusetts",
"National Institute on Alcohol Abuse & Alcoholism",
"The Cleveland Clinic Foundation",
"University of Louisville"
] | [
[
{
"name": "安纳白介素",
"lang": "CN"
},
{
"name": "Anakinra (Amgen)",
"lang": "EN"
}
],
[
{
"name": "己酮可可碱",
"lang": "CN"
},
{
"name": "Pentoxifylline",
"lang": "EN"
},
{
"name": "ペントキシフィリン",
"lang": "JP"
}
],
[... | null |
NCT01215331 | [
{
"id_field": "org_study_id",
"id_value": [
"08-057"
]
},
{
"id_field": "acronym",
"id_value": [
"DG5"
]
}
] | https://clinicaltrials.gov/study/NCT01215331 | Gestational Diabetes: Insulin or Oral Hypoglycemic Agents? | Gestational diabetes mellitus takes place in 2 steps. First, it is the consequence of insulin resistance due to the modifications of the pregnancy hormonal environment, and second, of the deficiency of the beta cells of the pancreas to respond by a sufficient insulin secretion. This physiopathology is closely connected... | Gestational Diabetes Mellitus: Insulin or Oral Hypoglycemic Agents? | [
{
"description": "Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glyc... | [
{
"design_group_description": "Rapid acting insulin and long acting insulin",
"design_group_title": "Insulin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Insulins ... | [
"Gestational Diabetes Mellitus"
] | [
"University of Sherbrooke"
] | [
"Fonds de la Recherche en Santé du Québec (Canada)"
] | [
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{
"name": "メトホルミン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "格列本脲",
"lang": "CN"
},
{
"name": "Glyburide",
"lang": "EN"
},
{... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DG5"
}
] |
NCT00810030 | [
{
"id_field": "org_study_id",
"id_value": [
"FER-IBD-07-COR"
]
},
{
"id_field": "acronym",
"id_value": [
"FER-IBD-COR"
]
}
] | https://clinicaltrials.gov/study/NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment. | Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease | [
{
"description": "Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum a... | [
{
"design_group_title": "FERINJECT® (Ferric carboxymaltose)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile s... | [
"Inflammatory Bowel Disease",
"Anemia",
"Iron Deficiency",
"Iron-Deficiency Anemia",
"Crohn's Disease",
"Ulcerative Colitis"
] | [
"Corden Pharma Fribourg SA"
] | [
"ClinStar LLC",
"PAREXEL International Corp."
] | [
[
{
"name": "羧基麦芽糖铁",
"lang": "CN"
},
{
"name": "Ferric Carboxymaltose",
"lang": "EN"
},
{
"name": "カルボキシマルトース第二鉄",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "FER-IBD-COR"
}
] |
NCT01275365 | [
{
"id_field": "org_study_id",
"id_value": [
"2012P001321"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"7R01AG037547"
]
},
{
"id_field": "acronym",
"id_value": [
"OPTIMen"
]
}
] | https://clinicaltrials.gov/study/NCT01275365 | Optimizing Protein Intake in Older Americans With Mobility Limitations | This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of dietary protein int... | Optimizing Protein Intake in Older Americans With Mobility Limitations | [
{
"description": "Testosterone enanthate 100 mg intramuscularly weekly",
"name": "Testosterone enanthate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Testosterone enanthate 100 mg intramuscularly weekly",
"name": "Testosterone enanthate",
... | [
{
"design_group_description": "Placebo injections weekly; 0.8 g/kg/day protein",
"design_group_title": "Placebo/Low Protein",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Placebo injections weekly; 1.3 g/kg/day protein",
"design_group_title": "Placebo/High Protein... | [
"Mobility Limitation"
] | [
"The Brigham & Women's Hospital, Inc."
] | [
"National Institute on Aging"
] | [
[
{
"name": "庚酸睾酮",
"lang": "CN"
},
{
"name": "Testosterone Enanthate",
"lang": "EN"
},
{
"name": "テストステロンエナント酸エステル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "28e4455a48a5da308d02ad42a500e5aa",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "OPTIMen"
}
] |
NCT03957668 | [
{
"id_field": "org_study_id",
"id_value": [
"19-04-0392"
]
}
] | https://clinicaltrials.gov/study/NCT03957668 | Efficacy and Safety of PEG 3350 for Treatment of Chronic Constipation | The aim of this study is to determine the efficacy and safety of PEG 3350 (polyethylene glycol 3350) for short-term treatment of chronic constipation in adults. | Efficacy and Safety of PEG 3350 for Treatment of Chronic Constipation | [
{
"description": "PEG 3350 17 g once daily for 14 days",
"name": "PEG 3350",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Lactulose 10 g once daily for 14 days",
"name": "Lactulose",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.",
"design_group_title": "PEG 3350",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354... | [
"Constipation - Functional"
] | [
"Fakultas Kedokteran, Universitas Indonesia"
] | [
"PT Meiji Indonesian Pharmaceutical Industries"
] | [
[
{
"name": "聚乙二醇3350",
"lang": "CN"
},
{
"name": "Polyethylene glycol 3350",
"lang": "EN"
}
]
] | null |
NCT00481364 | [
{
"id_field": "org_study_id",
"id_value": [
"06-4.1/2"
]
}
] | https://clinicaltrials.gov/study/NCT00481364 | Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients | This prospective, randomized, controlled study aims to investigate the effects of atorvastatin treatment in hemodialysis patients concerning progression of coronary artery calcification, progression of carotid artery intima-media thickness, endothelial function, and inflammation. | Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study | [
{
"description": "atorvastatin 40 mg/day",
"name": "atorvastatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "1 tb/day",
"name": "placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Atorvastatin 40 mg/day",
"design_group_title": "Statin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "atorvastatin 40 mg/day",
... | [
"Vascular Calcification",
"Atherosclerosis",
"Dyslipidemia",
"Inflammation"
] | [
"Ege Universitesi"
] | [
"Pfizer Inc."
] | [
[
{
"name": "阿托伐他汀钙",
"lang": "CN"
},
{
"name": "Atorvastatin Calcium",
"lang": "EN"
},
{
"name": "アトルバスタチンカルシウム水和物",
"lang": "JP"
}
]
] | null |
NCT01305109 | [
{
"id_field": "org_study_id",
"id_value": [
"BBIL/ROTA/021"
]
},
{
"id_domain": "CTRI/2010/091/000102",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"Clinical Trials Registry-India"
]
},
{
"id_field": "acronym",
"id_value": [... | https://clinicaltrials.gov/study/NCT01305109 | A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E | The trial is a phase III randomized, double-blind, placebo-controlled trial with the primary objective of evaluating the efficacy of three doses of ORV 116E, 10^5.0 FFU, against severe rotavirus gastroenteritis, in comparison with a placebo in India. | A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants | [
{
"description": "Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals",
"name": "ORV 116E",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"ROTAVAC"
],
"type": "Biological"
},
{
... | [
{
"design_group_description": "Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals",
"design_group_title": "Oral Rotavirus Vaccine 116E (ORV 116E)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "... | [
"Viral Gastroenteritis Due to Rotavirus"
] | [
"Bharat Biotech International Ltd."
] | [
"Ministry of Science and Technology",
"Program for Appropriate Technology in Health"
] | [
[
{
"name": "轮状病毒疫苗116E(Bharat Biotech International Ltd.)",
"lang": "CN"
},
{
"name": "Rotavirus vaccine 116E(Bharat Biotech International Ltd.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ROTAVAC"
}
] |
NCT00630812 | [
{
"id_field": "org_study_id",
"id_value": [
"DPM-CF-302"
]
}
] | https://clinicaltrials.gov/study/NCT00630812 | Long Term Administration of Inhaled Mannitol in Cystic Fibrosis | The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and quality of life. The r... | Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study | [
{
"description": "400 mg BD for 26 + 26 weeks",
"name": "inhaled mannitol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase",
"name": "Placebo comparator",
"nor... | [
{
"design_group_description": "active treatment",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "400 mg BD for 26 + 26 weeks",
"intervent... | [
"Cystic Fibrosis"
] | [
"Syntara Ltd."
] | [
"ethica Clinical Research Inc.",
"ReSolution Latin America"
] | [
[
{
"name": "甘露醇",
"lang": "CN"
},
{
"name": "Mannitol",
"lang": "EN"
},
{
"name": "D-マンニトール",
"lang": "JP"
}
]
] | null |
NCT06332274 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-503316-33-00"
]
},
{
"id_domain": "CSET number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2023/3720"
]
},
{
"id_field": "acronym",
"id_value": [
"UMBRELLA"
]
}
] | https://clinicaltrials.gov/study/NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular residual disease (MRD). When such traces are detected (we speak of MRD+ status), the risk o... | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | [
{
"description": "Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.<br/>Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cy... | [
{
"design_group_description": "Systemic treatment with tislelizumab monotherapy at the recommended dose of 400 mg administered intravenously every 6 weeks for a maximum of 9 cycles and followed-up as per standard of care (clinical examination plus imaging every 3 months the first year and every 6 months the sec... | [
"Cancer",
"Lung Cancer",
"Colo-rectal Cancer",
"Pancreas Cancer",
"Soft Tissue Sarcoma"
] | [
"Gustave Roussy, Cancer Campus, Grand Paris"
] | [
"Veracyte, Inc.",
"BeOne Medicines Ltd."
] | [
[
{
"name": "替雷利珠单抗",
"lang": "CN"
},
{
"name": "Tislelizumab",
"lang": "EN"
},
{
"name": "チスレリズマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "UMBRELLA"
}
] |
NCT04600167 | [
{
"id_field": "org_study_id",
"id_value": [
"NIMR-MB-002"
]
},
{
"id_field": "acronym",
"id_value": [
"PROTID"
]
}
] | https://clinicaltrials.gov/study/NCT04600167 | Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus | Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB and HIV and it has been estimated that 15-30% of TB disease may be attributable to diabetes globally. This may be expected to rise subst... | A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People With Diabetes | [
{
"description": "Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.",
"name": "Isoniazid and Rifapentine (INH-RPT)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"3HP"
],
"type": "Drug"
},
{
"descripti... | [
{
"design_group_description": "Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.",
"design_group_title": "Isoniazid and Rifapentine (INH-RPT)",
"design_group_type": "Experimental",
"design_group_type_... | [
"Diabetes Mellitus",
"Tuberculosis"
] | [
"The National Institute For Medical Research"
] | [
"Makerere University",
"St. George's University of London",
"King's College London",
"Kilimanjaro Christian Medical College",
"University of Otago",
"Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands"
] | [
[
{
"name": "利福喷丁",
"lang": "CN"
},
{
"name": "Rifapentine",
"lang": "EN"
}
],
[
{
"name": "异烟肼",
"lang": "CN"
},
{
"name": "Isoniazid",
"lang": "EN"
},
{
"name": "イソニアジド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PROTID"
}
] |
NCT02268045 | [
{
"id_field": "org_study_id",
"id_value": [
"RTXM83-AC-01-11"
]
}
] | https://clinicaltrials.gov/study/NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | This is a multicenter, double-blind, randomized study comparing the efficacy, pharmacokinetics (PK)/pharmacodynamics (PD), safety and immunogenicity profile of RTXM83 (rituximab biosimilar) vs reference rituximab (MabThera®), both with CHOP, as first-line treatment of Diffuse-Large-B-Cell-Lymphoma (DLBCL).<br/>Rituxima... | A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line | [
{
"description": "Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Da... | [
{
"design_group_description": "Active Ingredient: Rituximab (Biosimilar)",
"design_group_title": "RTXM83",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Rituximab biosimil... | [
"Diffuse Large B-cell Lymphoma"
] | [
"mAbxience Research SL"
] | [
"Key Oncologics (Pty) Ltd.",
"Tecnoquímicas SA",
"Libbs Farmacêutica Ltda.",
"Innogene Kalbiotech Pte Ltd.",
"Laboratorios de Productos Éticos C.E.I.S.A.",
"Laboratorio Elea Phoenix SA",
"NANOLEK LLC"
] | [
[
{
"name": "利妥昔单抗生物类似药 (mAbxience)",
"lang": "CN"
},
{
"name": "Rituximab biosimilar (mAbxience)",
"lang": "EN"
}
]
] | null |
NCT04338022 | [
{
"id_field": "org_study_id",
"id_value": [
"MS200527_0080"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-004972-20"
]
}
] | https://clinicaltrials.gov/study/NCT04338022 | Study of Evobrutinib in Participants With RMS (evolutionRMS 1) | The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (D... | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1) | [
{
"description": "Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of ... | [
{
"design_group_title": "Teriflunomide",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once dai... | [
"Relapsing Multiple Sclerosis"
] | [
"Merck Healthcare KGaA"
] | [
"EMD Serono Research & Development Institute, Inc."
] | [
[
{
"name": "埃沃布鲁替尼",
"lang": "CN"
},
{
"name": "Evobrutinib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "285de0a2a9d389e8e502e02a048394e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "d385aaae2a498a03d22dea45554ea234",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "evo... |
NCT00673920 | [
{
"id_field": "org_study_id",
"id_value": [
"ACT4394g"
]
},
{
"id_field": "secondary_id",
"id_value": [
"WA20496"
]
},
{
"id_field": "acronym",
"id_value": [
"FEATURE"
]
}
] | https://clinicaltrials.gov/study/NCT00673920 | A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy | This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy. Patients will be randomized 2:2:1 to receive 1) infusions of ocrelizumab 200mg iv on Days 1 and 15, 2) infusions of ocrelizumab 400m... | A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy | [
{
"description": "Oral or parenteral repeating dose",
"name": "Methotrexate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (O... | [
{
"design_group_description": "Participants received matching placebo:<br/>* on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)<br/>* on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate grou... | [
"Rheumatoid Arthritis"
] | [
"Genentech, Inc."
] | [
"Roche Pharma AG"
] | [
[
{
"name": "奥瑞利珠单抗",
"lang": "CN"
},
{
"name": "Ocrelizumab",
"lang": "EN"
}
],
[
{
"name": "甲氨蝶呤钠",
"lang": "CN"
},
{
"name": "Methotrexate Sodium",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "FEATURE"
}
] |
NCT00017277 | [
{
"id_field": "org_study_id",
"id_value": [
"EORTC-22996-24002"
]
},
{
"id_field": "secondary_id",
"id_value": [
"EORTC-22996"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ARO-EORTC-22996"
]
},
{
"id_field": "secondary_id",
"id_value": [... | https://clinicaltrials.gov/study/NCT00017277 | Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer | RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may help prevent or treat cancer-related anemia. It is not yet known whether radiation therapy is more effective with or without epoetin alfa in treating head and neck cancer.<br/>PURPOSE: Randomized phase III trial to compare the ... | A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma | [
{
"name": "epoetin alfa",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"name": "radiation therapy",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"type": "Radiation"
}
] | null | [
"Head and Neck Cancer"
] | [
"European Organisation for Research & Treatment of Cancer"
] | [
"Charité - Universitätsmedizin Berlin"
] | [
[
{
"name": "促红素α",
"lang": "CN"
},
{
"name": "Epoetin Alfa",
"lang": "EN"
},
{
"name": "エポエチン アルファ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02901041 | [
{
"id_field": "org_study_id",
"id_value": [
"2R01AA015923-06"
]
}
] | https://clinicaltrials.gov/study/NCT02901041 | Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism | Alcoholism is the third leading cause of preventable death in the US, accounting for 80,000 deaths annually. Almost 18 million US adults have alcohol use disorder (AUD); however, approved medications for the treatment of AUD has shown limited effectiveness.<br/>Zonisamide (ZON), a broad spectrum anticonvulsant, has pro... | Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism | [
{
"description": "ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.... | [
{
"design_group_description": "Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.",
"design_gr... | [
"Alcohol Dependence"
] | [
"Winthrop University"
] | [
"University of Houston",
"McLean Hospital, Inc."
] | [
[
{
"name": "唑尼沙胺",
"lang": "CN"
},
{
"name": "Zonisamide",
"lang": "EN"
},
{
"name": "ゾニサミド",
"lang": "JP"
}
]
] | null |
NCT00826644 | [
{
"id_field": "org_study_id",
"id_value": [
"CSCLC-0810"
]
},
{
"id_field": "acronym",
"id_value": [
"COMBAT"
]
}
] | https://clinicaltrials.gov/study/NCT00826644 | Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, e... | A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer | [
{
"description": "Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks",
"name": "Belotecan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Camtobell"
],
"type": "Drug"
},
{
"description": "Etoposide 100mg/㎡/day for Day 1 to 3, repeated every... | [
{
"design_group_title": "Belotecan plus Cisplatin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks",
"int... | [
"Carcinoma, Small Cell"
] | [
"Chonnam National University Hospital"
] | [
"Chong Kun Dang Pharmaceutical Corp."
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
],
[
{
"name": "盐酸贝洛替康",
"lang": "CN"
},
{
"name": "Belotecan Hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COMBAT"
}
] |
NCT04194216 | [
{
"id_field": "org_study_id",
"id_value": [
"53854"
]
}
] | https://clinicaltrials.gov/study/NCT04194216 | Antibiotic Prophylaxis in Rhinoplasty | This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral d... | Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics | [
{
"description": "Treatment Arm A",
"name": "Intra-operative single intravenous(iv) dose of \"cephalexin\" 2 g or \"clindamycin\" 900 mg.",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"cleocin (clindamycin)",
"kelfex (cephalexin)"
],
"type": "Drug"
},... | [
{
"design_group_description": "Intra-operative single intravenous(iv) dose of \"cephalexin\" 2 g or \"clindamycin\" 900 mg.",
"design_group_title": "Treatment arm A",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": ... | [
"Nasal Obstruction",
"Nasal Surgical Procedures"
] | [
"Stanford University"
] | [
"Loma Linda University",
"Washington University School of Medicine",
"University of Kansas",
"Vanderbilt University School of Medicine",
"Harvard University",
"University of Washington",
"Duke University"
] | [
[
{
"name": "头孢氨苄",
"lang": "CN"
},
{
"name": "Cephalexin",
"lang": "EN"
},
{
"name": "セファレキシン",
"lang": "JP"
}
],
[
{
"name": "盐酸克林霉素",
"lang": "CN"
},
{
"name": "Clindamycin Hydrochloride",
"lang": "EN"
},
... | null |
NCT00190632 | [
{
"id_field": "org_study_id",
"id_value": [
"2690"
]
},
{
"id_field": "secondary_id",
"id_value": [
"F1J-MC-SBAY"
]
}
] | https://clinicaltrials.gov/study/NCT00190632 | To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence | This is an on-going study to evaluate the long-term safety and maintenance of effect of duloxetine in patients suffering with stress urinary incontinence. | Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence | [
{
"name": "Duloxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Stress Urinary Incontinence"
] | [
"Eli Lilly & Co."
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "盐酸度洛西汀",
"lang": "CN"
},
{
"name": "Duloxetine Hydrochloride",
"lang": "EN"
},
{
"name": "デュロキセチン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00861276 | [
{
"id_field": "org_study_id",
"id_value": [
"Prot 29/99"
]
},
{
"id_field": "acronym",
"id_value": [
"SUNIC"
]
}
] | https://clinicaltrials.gov/study/NCT00861276 | Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit | Objective: To assess the impact of instructional guidance in the regular use of use nicotine nasal spray (NNS) on the true use of NNS during the first three weeks of smoking cessation for heavy smokers who are willing to quit.<br/>Methods: This randomized, open, controlled trial included 50 patients who were heavy smok... | Use of Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit: a Randomized Controlled Trial | [
{
"description": "During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).",
"name": "Nasal Spray Nicotine Substitute (Experimental)",
"normalized_type": "3d1aa88261d6... | [
{
"design_group_description": "Arm instructed to use spray at least once an hour when awake.",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Dur... | [
"Smoking Cessation"
] | [
"University of Lausanne"
] | [
"Pharmacia Corp."
] | [
[
{
"name": "尼古丁",
"lang": "CN"
},
{
"name": "Nicotine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SUNIC"
}
] |
NCT01922115 | [
{
"id_field": "org_study_id",
"id_value": [
"13-1352"
]
},
{
"id_field": "acronym",
"id_value": [
"ACE"
]
}
] | https://clinicaltrials.gov/study/NCT01922115 | The Effect of Anticholinergics on Cognitive Function in the Elderly | Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of this medication is cognitive dysfunction. OAB is more prevalent in the elderly population - a group that also has a higher baseline risk of cognitive dysfunction. Our objective is to evaluate the effect of an anticholinergic me... | The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial | [
{
"description": "Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.",
"name": "Trospium Chloride",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).",
"design_group_title": "TROSPIUM CHLORIDE",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e... | [
"Mental Competency",
"Urinary Bladder, Overactive",
"Cognitive Function"
] | [
"The University of North Carolina at Chapel Hill"
] | [
"American Urogynecologic Society"
] | [
[
{
"name": "曲司氯铵",
"lang": "CN"
},
{
"name": "Trospium Chloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "52eaae5085e989a83e8899830aaea223",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ACE"
}
] |
NCT00314613 | [
{
"id_field": "org_study_id",
"id_value": [
"7858"
]
},
{
"id_field": "secondary_id",
"id_value": [
"7858"
]
},
{
"id_field": "secondary_id",
"id_value": [
"RIS-NAP-4007"
]
}
] | https://clinicaltrials.gov/study/NCT00314613 | Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal | Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment. | Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal | [
{
"name": "Antipsychotic/Risperidone Consta",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "multiple_drugs",
"type": "Drug"
}
] | null | [
"Schizophrenia"
] | [
"Duke University"
] | [
"Janssen LP"
] | [
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"name": "リスペリドン",
"lang": "JP"
}
]
] | null |
NCT03460041 | [
{
"id_field": "org_study_id",
"id_value": [
"N-59-2017"
]
}
] | https://clinicaltrials.gov/study/NCT03460041 | Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries | This study will be performed in Abo Elreesh Pediatric Hospital / Cairo University after obtaining approval by the University Ethics Committee, and a written informed consent from the parents or guardians.<br/>Thirty six patients will be randomly assigned using an online randomization program (http://www.randomizer.org)... | Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries | [
{
"description": "caudal magnesium sulphate added to bupivacaine for pain management",
"name": "Magnesium Sulfate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Caudal dexmetedomedine added to bupivacaine for pain management",
"name": "Dexmet... | [
{
"design_group_title": "Control",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Caudal bupivacaine for pain management",
"intervention_name": "Bupivacaine",
... | [
"Pain in Pediatric Patients"
] | [
"Cairo University"
] | [
"Cairo University"
] | [
[
{
"name": "盐酸右美托咪定",
"lang": "CN"
},
{
"name": "Dexmedetomidine Hydrochloride",
"lang": "EN"
},
{
"name": "デクスメデトミジン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "硫酸镁",
"lang": "CN"
},
{
"name": "Magnesium Sulfate",
"lang": ... | null |
NCT05393505 | [
{
"id_field": "org_study_id",
"id_value": [
"CTC2178HKU1"
]
},
{
"id_field": "acronym",
"id_value": [
"FRANCiS-NF"
]
}
] | https://clinicaltrials.gov/study/NCT05393505 | Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection | This is a comparative study for adult participants with cancer who are suspected to have neutropenic fever (or fever with low neutrophil count) in emergency department. Neutrophil is a kind of defensive white blood cell combating against infection, especially by bacteria and fungi. Low neutrophil can be part of the dis... | Fast-track Absolute Neutrophil Count in Suspected Neutropenic Fever (The FRANCiS-NF Trial): A Single-centre, Pragmatic, Open-label, Randomised, Controlled Trial | [
{
"description": "Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours",
"name": "Meropenem Injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Given if patient is allergic to beta lact... | [
{
"design_group_description": "Patient's blood sample will be expedited for complete blood count with differentials. Intravenous antibiotic is given depending on absolute neutrophil count. If neutropenia is present, broad-spectrum antibiotic (meropenem 1 g or levofloxacin 500 mg) will be given after septic work... | [
"Neutropenic Fever"
] | [
"The University of Hong Kong"
] | [
"Queen Mary Hospital"
] | [
[
{
"name": "左氧氟沙星",
"lang": "CN"
},
{
"name": "Levofloxacin",
"lang": "EN"
},
{
"name": "レボフロキサシン水和物",
"lang": "JP"
}
],
[
{
"name": "美洛培南",
"lang": "CN"
},
{
"name": "Meropenem",
"lang": "EN"
},
{
"na... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "FRANCiS-NF"
}
] |
NCT00638508 | [
{
"id_field": "org_study_id",
"id_value": [
"06/07/VA3"
]
}
] | https://clinicaltrials.gov/study/NCT00638508 | ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management | After surgery it is normal to experience some pain at the site of operation. In order to reduce the pain, medication such as Morphine is injected into a vein using a Patient Controlled Analgesia (PCA) pump that is kept at bed side, and is activated by the patient when needed. However, Morphine is an opioid drug, which ... | The Analgesic Efficacy of Continuous Infusion of Ketorolac and Ropivacaine at the Wound Site Using ON-Q Pump for Postoperative Pain Management | [
{
"description": "Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day",
"name": "Ketorolac",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Toradol"
],
"type": "Drug"
},
{
"description": "Patients will receive Ketorolac at 5 mg/hr plus 0... | [
{
"design_group_description": "Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day",
"design_group_title": "Ketorolac",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention... | [
"Postoperative Pain"
] | [
"Maimonides Medical Center"
] | [
"I-Flow Corp."
] | [
[
{
"name": "盐酸罗哌卡因",
"lang": "CN"
},
{
"name": "Ropivacaine Hydrochloride",
"lang": "EN"
},
{
"name": "ロピバカイン塩酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "酮咯酸氨丁三醇",
"lang": "CN"
},
{
"name": "Ketorolac Tromethamine",
"lan... | null |
NCT01975051 | [
{
"id_field": "org_study_id",
"id_value": [
"PR-12057"
]
}
] | https://clinicaltrials.gov/study/NCT01975051 | A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) | We hypothesize that PKDL develop after SSG as well as after Miltefosine mono-therapy for VL; anti-inflammatory cytokines such as IL-10, TGF-β, serum lipids play key role for its pathogenesis & PKDL patients are genetically predisposed; diagnostic tool based on immunofluorescence technique will be more sensitive than sl... | A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) | [
{
"description": "Tablet Miltefosine 100 mg in two devided doses for 12 weeks",
"name": "Mitefosine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Brand name: Impavido"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.",
"design_group_title": "Miltefosine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_des... | [
"Post-kala-azar Dermal Leishmaniasis"
] | [
"International Centre for Diarrhoeal Disease Research, Bangladesh"
] | [
"University of Nagasaki"
] | [
[
{
"name": "米替福新",
"lang": "CN"
},
{
"name": "Miltefosine",
"lang": "EN"
}
]
] | null |
NCT03442972 | [
{
"id_field": "org_study_id",
"id_value": [
"16-6368.2"
]
},
{
"id_field": "acronym",
"id_value": [
"GLP-2 Biopsy"
]
}
] | https://clinicaltrials.gov/study/NCT03442972 | Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids | Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride from the gut is not known. The research team in ... | Investigating the Release of Stored Enteral Lipids in Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans | [
{
"description": "Teduglutide",
"name": "Teduglutide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Teduglutide, up to 0.05mg/kg, subcutaneous, single dose",
"design_group_title": "Teduglutide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": ... | [
"Hyperlipidemias"
] | [
"University Health Network"
] | [
"Kensington Screening Clinic"
] | [
[
{
"name": "替度格鲁肽",
"lang": "CN"
},
{
"name": "Teduglutide Recombinant",
"lang": "EN"
},
{
"name": "テデュグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GLP-2 Biopsy"
}
] |
NCT01813773 | [
{
"id_field": "org_study_id",
"id_value": [
"THE A.C.T. STUDY"
]
},
{
"id_field": "acronym",
"id_value": [
"ACT"
]
}
] | https://clinicaltrials.gov/study/NCT01813773 | Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study | To assess the safety of intravitreal aflibercept injection in the treatment of proliferative diabetic retinopathy (PDR) by evaluating the incidence and severity of adverse events. | Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study | [
{
"description": "EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein mol... | [
{
"design_group_description": "Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.",
"design_group_title": "Group ... | [
"Proliferative Diabetic Retinopathy"
] | [
"Ophthalmic Consultants of Long Island"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
[
{
"name": "阿柏西普",
"lang": "CN"
},
{
"name": "Aflibercept",
"lang": "EN"
},
{
"name": "アフリベルセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ACT"
}
] |
NCT04721795 | [
{
"id_field": "org_study_id",
"id_value": [
"ERC/2020/10/05"
]
},
{
"id_domain": "NHREC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NHREC/27/02/2009a"
]
},
{
"id_field": "acronym",
"id_value": [
"ATORTUB"
]
}
] | https://clinicaltrials.gov/study/NCT04721795 | Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis) | Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally, with more than 10 million new cases and over 2 million deaths annually. Developing countries bear the greatest brunt of the disease. The long duration of current treatment is associated with poor complia... | Repurposing a Lipid Lowering Drug to Treat Tuberculosis: Effectiveness of Statins as Adjuvant to Treatment of Pulmonary Tuberculosis in Nigeria | [
{
"description": "Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis ... | [
{
"design_group_description": "Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti ... | [
"Tuberculosis, Pulmonary",
"Tuberculosis"
] | [
"Obafemi Awolowo University"
] | [
"Cures Within Reach"
] | [
[
{
"name": "阿托伐他汀锶",
"lang": "CN"
},
{
"name": "Atorvastatin strontium",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ATORTUB"
}
] |
NCT00128466 | [
{
"id_field": "org_study_id",
"id_value": [
"CDC-NCID-3700"
]
}
] | https://clinicaltrials.gov/study/NCT00128466 | Treatment and Diagnosis of Plague | This clinical trial will compare the effectiveness of streptomycin, which historically is the standard drug for treatment of plague, with gentamicin. The hypothesis is that gentamicin is not inferior to streptomycin but that it will have less severe side effects. The study is being done in Madagascar because that count... | Safety and Efficacy of Gentamicin Versus Streptomycin for the Treatment of Naturally Occurring Human Plague and Evaluation of Rapid Diagnostic Test Kits for Yersinia Pestis | [
{
"name": "gentamicin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "streptomycin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Plague"
] | [
"Centers for Disease Control & Prevention"
] | [
"Uganda Ministry of Health",
"US Food & Drug Administration"
] | [
[
{
"name": "硫酸链霉素",
"lang": "CN"
},
{
"name": "Streptomycin Sulfate",
"lang": "EN"
},
{
"name": "ストレプトマイシン硫酸塩",
"lang": "JP"
}
],
[
{
"name": "硫酸庆大霉素",
"lang": "CN"
},
{
"name": "Gentamicin Sulfate",
"lang": "EN"
... | null |
NCT00517712 | [
{
"id_field": "org_study_id",
"id_value": [
"IAPLSG2004"
]
},
{
"id_field": "secondary_id",
"id_value": [
"BT/PR4460/Med/14/531/2003"
]
},
{
"id_field": "acronym",
"id_value": [
"IAPLSG04"
]
}
] | https://clinicaltrials.gov/study/NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia | There is very limited data on the use of arsenic trioxide in newly diagnosed patients with acute promyelocytic leukemia. The use of arsenic trioxide was limited to relapsed patients mainly because of the superior efficacy of ATRA as primary therapy for newly diagnosed APML. Though the early study by Niu et al showed 72... | Molecular Remission With Arsenic Trioxide in Acute Promyelocytic Leukemia: Indian APL Study Group - IAPLSG | [
{
"description": "duration of maintenance therapy, 6 months versus 12 months",
"name": "Single agent arsenic trioxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Duration of maintenance therapy with single agent ATO of 12 months",
"design_group_title": "A",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_descript... | [
"Acute Promyelocytic Leukemia"
] | [
"Christian Medical College & Hospital"
] | [
"Ministry of Science and Technology"
] | [
[
{
"name": "三氧化二砷",
"lang": "CN"
},
{
"name": "Arsenic Trioxide",
"lang": "EN"
},
{
"name": "三酸化二ヒ素",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IAPLSG04"
}
] |
NCT04345718 | [
{
"id_field": "org_study_id",
"id_value": [
"NIDA CTN 0098A"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5UG1DA040316-05"
]
},
{
"id_field": "acronym",
"id_value": [
"EXHITENTRE"
]
}
] | https://clinicaltrials.gov/study/NCT04345718 | EXHIT ENTRE Comparative Effectiveness Trial | This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction consultation service (ACS) and agreeing t... | Exemplar Hospital Initiation Trial to Enhance Treatment Engagement - Comparative Effectiveness Trial of Extended Release Buprenorphine Versus Treatment as Usual for Hospitalized Patients With Opioid Use Disorder | [
{
"description": "XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).",
"name": "Extended Release Buprenorphine",
"normalized_t... | [
{
"design_group_description": "Single subcutaneous injection of a 28-day formulation of extended-release buprenorphine within 72 hours of anticipated hospital discharge.",
"design_group_title": "Interventional",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354... | [
"Substance Use Disorder",
"Opioid Use Disorder, Moderate",
"Opioid Use Disorder, Severe"
] | [
"Hennepin Healthcare Research Institute"
] | [
"The Emmes Co. LLC",
"National Institute on Drug Abuse",
"Hennepin Healthcare Research Institute"
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EXHITENTRE"
}
] |
NCT03217734 | [
{
"id_field": "org_study_id",
"id_value": [
"A16-241"
]
},
{
"id_field": "acronym",
"id_value": [
"MAP"
]
}
] | https://clinicaltrials.gov/study/NCT03217734 | MAP Study: Methotrexate and Adalimumab in Psoriasis | Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX. | MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation | [
{
"description": "Subcutaneous Injection",
"name": "Adalimumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Humira"
],
"type": "Biological"
},
{
"description": "Oral Tablet",
"name": "Methotrexate",
"normalized_type": "3d1aa88261d64c03841372... | [
{
"design_group_description": "Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks",
"design_group_title": "ADA and Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": ... | [
"Psoriasis"
] | [
"Bakersfield Dermatology & Skin Cancer Medical Group"
] | [
"AbbVie, Inc."
] | [
[
{
"name": "阿达木单抗",
"lang": "CN"
},
{
"name": "Adalimumab",
"lang": "EN"
},
{
"name": "アダリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "甲氨蝶呤钠",
"lang": "CN"
},
{
"name": "Methotrexate Sodium",
"lang": "EN"
}
]
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MAP"
}
] |
NCT00272324 | [
{
"id_field": "org_study_id",
"id_value": [
"5R01CA059005-12"
]
}
] | https://clinicaltrials.gov/study/NCT00272324 | Aspirin/Folate Prevention of Large Bowel Polyps | This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel. | Aspirin/Folate Prevention of Large Bowel Polyps | [
{
"name": "Aspirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Folate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Colorectal Cancer",
"Polyps",
"Adenomas"
] | [
"Dartmouth-Hitchcock Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "叶酸",
"lang": "CN"
},
{
"name": "Folic Acid",
"lang": "EN"
}
],
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
"name": "サリチル酸",
"lang": "JP"
}
]
] | null |
NCT03094429 | [
{
"id_field": "org_study_id",
"id_value": [
"SNR-05"
]
}
] | https://clinicaltrials.gov/study/NCT03094429 | An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults | This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.<br/>Part 1 Objectives: There are two primary objectives for Part 1 of this study:<br/>1. To evaluate, i... | An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults | [
{
"description": "2000 mg/day or 1000 mg/day, twice daily",
"name": "NaBen®",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "0 mg total, twice daily",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Ot... | [
{
"design_group_description": "Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.",
"design_group_title": "NaBen® - 2000 mg/day",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"interv... | [
"Refractory Schizophrenia"
] | [
"SyneuRx International (Taiwan) Corp."
] | [
"Amarex Clinical Research LLC"
] | [
[
{
"name": "苯甲酸钠",
"lang": "CN"
},
{
"name": "Sodium Benzoate",
"lang": "EN"
},
{
"name": "安息香酸ナトリウム",
"lang": "JP"
}
]
] | null |
NCT01691768 | [
{
"id_field": "org_study_id",
"id_value": [
"CAPRISA008"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT01645813"
]
}
] | https://clinicaltrials.gov/study/NCT01691768 | Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services | The purpose of this study is to assess the effectiveness of an implementation model which integrates tenofovir gel provision into existing family planning services. | Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa | [
{
"description": "Participants will be randomized to receive 1% tenofovir gel through either:<br/>* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or<br/>* The CAPRISA res... | [
{
"design_group_description": "1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery",
"design_group_title": "Intervention",
"design_group_type": "Experimen... | [
"HIV"
] | [
"Centre for the AIDS Programme of Research in South Africa"
] | [
"FHI 360, Inc.",
"Contraception Research and Development",
"The Institute for Healthcare Improvement",
"Gilead Sciences, Inc."
] | [
[
{
"name": "替诺福韦",
"lang": "CN"
},
{
"name": "Tenofovir",
"lang": "EN"
}
]
] | null |
NCT00063076 | [
{
"id_field": "org_study_id",
"id_value": [
"DM02-164"
]
}
] | https://clinicaltrials.gov/study/NCT00063076 | Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata | The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The safety and tolerability of this drug will also be studied.<br/>Objectives:<br/>1. Determine the safety and tolerability of Targretin® Gel 1%... | A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata | [
{
"description": "Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.",
"name": "Targretin Gel 1%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Targretin® (bexarotene) Gel 1%, treat half head",
"design_group_title": "Targretin®",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Alopecia... | [
"Alopecia Areata"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Ligand Pharmaceuticals, Inc."
] | [
[
{
"name": "贝沙罗汀",
"lang": "CN"
},
{
"name": "Bexarotene",
"lang": "EN"
},
{
"name": "ベキサロテン",
"lang": "JP"
}
]
] | null |
NCT00624923 | [
{
"id_field": "org_study_id",
"id_value": [
"CHS 06-13"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P50HL083813"
]
},
{
"id_domain": "Beth Israel Deaconess Medical Center, Boston, MA, USA",
"id_field": "secondary_id"... | https://clinicaltrials.gov/study/NCT00624923 | Targeting Inflammation Using Salsalate in CardioVascular Disease | The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote a chronic, subacute inflammatory state that participates in the development and progression of atherosclerosis. We will evaluate the effects of targeting inflammation using the anti-inflammatory drug salsalate, compared to pla... | Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD) | [
{
"description": "Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months",
"name": "Salsalate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Disalcid"
],
"type": "Drug"
},
{
"description": "Placebo matched to Salsalate,... | [
{
"design_group_description": "Salsalate",
"design_group_title": "1- Active Pharmacologic",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Salsalate, 500 mg, seven tablets ... | [
"Coronary Artery Disease",
"Overweight"
] | [
"Joslin Diabetes Center, Inc."
] | [
"Tufts Medical Center, Inc.",
"National Heart, Lung & Blood Institute",
"Beth Israel Deaconess Medical Center, Inc."
] | [
[
{
"name": "双水杨酯",
"lang": "CN"
},
{
"name": "Salsalate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "2ea42e25e009e5ea5e8e982ad3e3d028",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "304aae52e939a28e58aa4253882a90da",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source... |
NCT04452474 | [
{
"id_field": "org_study_id",
"id_value": [
"CL04041080"
]
}
] | https://clinicaltrials.gov/study/NCT04452474 | Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). | The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29. | A Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19) | [
{
"description": "solution for subcutaneous administration 160 mg/mL",
"name": "Olokizumab 64 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package",
"name": "Plac... | [
{
"design_group_description": "Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy",
"design_group_title": "Olokizumab 64 mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b35448... | [
"COVID-19"
] | [
"R-Pharm JSC"
] | [
"Cromos Pharma LLC",
"Labcorp Drug Development, Inc."
] | [
[
{
"name": "Olokizumab",
"lang": "EN"
}
]
] | null |
NCT04098653 | [
{
"id_field": "org_study_id",
"id_value": [
"Dec+BUCYvsBUCY-Myeloid tumors"
]
}
] | https://clinicaltrials.gov/study/NCT04098653 | Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT | Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for myeloid tumors, such as acute myeloid leukemia and myelodysplastic syndrome. Unfortunately, some patients relapsed after allo-HSCT. In this prospective randomized controlled stud... | Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | [
{
"description": "Decitabine was administered at 20mg/m2/day on days -14 and -10.",
"name": "Decitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.",
"name": "Busulfan (BU)",
... | [
{
"design_group_description": "For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.",
"design_group_title": "Decitabine + BUCY",
"... | [
"Allogeneic Hematopoietic Stem Cell Transplantation",
"Conditioning",
"Myeloid Tumors"
] | [
"Nanfang Hospital"
] | [
null,
"Sun Yat-Sen Memorial Hospital",
"The Third Affiliated Hospital, Sun Yat-Sen University",
"Peking University People's Hospital"
] | [
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name":... | null |
NCT00323804 | [
{
"id_field": "org_study_id",
"id_value": [
"ANRS HC15 NRfi"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2005-002937-11"
]
}
] | https://clinicaltrials.gov/study/NCT00323804 | Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. | Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop liver fibrosis leading to cirrhosis. Maintenance low dose pegylated interferon therapy of fibrosis is currently under investigation in large multicenter trials. The aim of our study is to assess if peginterferon alpha2b plus r... | Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients. | [
{
"description": "PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36",
"name": "Peginterferon alfa-2b",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36",
... | [
{
"design_group_description": "Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36",
"design_group_title": "Randomised PegIFN alfa 2b + ribavirin (RBV) arm",
... | [
"Hepatitis C, Chronic",
"Liver Fibrosis"
] | [
"France Recherche Nord & Sud SIDA HIV-Hepatites"
] | [
"Centre Hospitalier Universitaire de Rennes",
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "聚乙二醇干扰素α-2b注射(Merck & Co)",
"lang": "CN"
},
{
"name": "Peginterferon alfa-2b(Merck & Co)",
"lang": "EN"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
{
"name": "リバビリン",
... | null |
NCT05378698 | [
{
"id_field": "org_study_id",
"id_value": [
"TRALIS/TRALO-2260"
]
},
{
"id_field": "acronym",
"id_value": [
"TRALIS"
]
},
{
"id_field": "secondary_id",
"id_value": [
"TRALIS/TRALO-2260"
]
}
] | https://clinicaltrials.gov/study/NCT05378698 | Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation | The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood. A better understanding of the mechanisms underlying the clinical effects of tralokinumab would be of great clinical benefit since it may ultimately help us to identify more precisely ca... | Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation (TRALIS) | [
{
"description": "2 Arms 20 patients 5 healthy controls",
"name": "Application of Tralokinumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Healthy controls",
"design_group_title": "Healthy arm",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Patients with AD",
"design_group_title": "Tralokinumab",
"design_group_type": "Active Comparator",
"design_group_type_normal... | [
"Atopic Dermatitis"
] | [
"University of Zurich"
] | [
"Hochgebirgsklinik Davos"
] | [
[
{
"name": "曲罗芦单抗",
"lang": "CN"
},
{
"name": "Tralokinumab",
"lang": "EN"
},
{
"name": "トラロキヌマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TRALIS"
}
] |
NCT01021696 | [
{
"id_field": "org_study_id",
"id_value": [
"2008-007490-20"
]
}
] | https://clinicaltrials.gov/study/NCT01021696 | Pain in Patients With Dementia and Behavioural Disturbances | In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitat... | The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial | [
{
"description": "Paracetamol Max. dose: 3g/d",
"name": "Paracetamol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Individual pain treatment"
],
"type": "Drug"
},
{
"description": "Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d",
"name": "Morphin... | [
{
"design_group_description": "Control group",
"design_group_title": "Treatment as usual",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Intervention group",
"design_group_title": "Paracetamol",
"design_group_type": "Active Comparator",
"design_group_type_n... | [
"Dementia",
"Pain",
"Agitation"
] | [
"University of Bergen"
] | [
"Noregs forskingsråd"
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "普瑞巴林",
"lang": "CN"
},
{
"name": "Pregabalin",
"lang": "EN"
}... | null |
NCT06549634 | [
{
"id_field": "org_study_id",
"id_value": [
"23-270"
]
},
{
"id_field": "secondary_id",
"id_value": [
"23-270"
]
}
] | https://clinicaltrials.gov/study/NCT06549634 | Biomarkers of AKI in Patients Receiving Daratumumab | The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are:<br/>To measure changes in plasma and urinary biomarkers ... | Biomarkers of AKI in Patients With Multiple Myeloma Receiving Daratumumab: A Pilot Study | [
{
"description": "Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration",
"name": "Daratumumab",
"normalized_type": "3d1aa... | [
{
"design_group_description": "Patients with multiple myeloma being newly initiated on daratumumab",
"design_group_title": "Patients with multiple myeloma",
"intervention": [
{
"intervention_description": "Daratumumab is not being administered as part of the study. Patients will receive da... | [
"Acute Kidney Injury",
"Multiple Myeloma",
"Light Chain Nephropathy"
] | [
"The Brigham & Women's Hospital, Inc."
] | [
"Janssen Pharmaceuticals, Inc."
] | [
[
{
"name": "达雷妥尤单抗",
"lang": "CN"
},
{
"name": "Daratumumab",
"lang": "EN"
},
{
"name": "ダラツムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00001024 | [
{
"id_field": "org_study_id",
"id_value": [
"DATRI 003"
]
},
{
"id_domain": "DAIDS ES Registry Number",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"11734"
]
},
{
"id_field": "secondary_id",
"id_value": [
"11734;DATRI ... | https://clinicaltrials.gov/study/NCT00001024 | The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS | Immunopathogenesis objectives: To compare and quantitatively determine HIV burden and HIV replication in peripheral blood (PB) and lymphoid tissue (LT). To determine the degree to which antiretroviral therapy alters HIV replication in LT.<br/>Clinical objectives: To gain insight into the degree of correlation between i... | A Multicenter, Open-Label Study of Viral Burden in Peripheral Blood Versus Lymphoid Tissue Before and After Antiretroviral Therapy in HIV-Infected Individuals Without AIDS (NOTE: One Arm Receives no Treatment) | [
{
"name": "Zidovudine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Didanosine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"HIV Infections"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"Glaxo Wellcome SA",
"Bristol Myers Squibb Co."
] | [
[
{
"name": "齐多夫定",
"lang": "CN"
},
{
"name": "Zidovudine",
"lang": "EN"
},
{
"name": "ジドブジン",
"lang": "JP"
}
],
[
{
"name": "去羟肌苷",
"lang": "CN"
},
{
"name": "Didanosine",
"lang": "EN"
}
]
] | null |
NCT00280215 | [
{
"id_field": "org_study_id",
"id_value": [
"2203-05"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NIH grant # DK 73354"
]
}
] | https://clinicaltrials.gov/study/NCT00280215 | Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria | This study will test the effectiveness of two medications: ACEI (angiotensin converting enzyme inhibitor)and ARB (angiotensin receptor blocker) in reducing the renal injury induced by hyperoxaluria in patients with Primary Hyperoxaluria.<br/>Hypothesis: Calcium oxalate crystal deposition in the kidney causes inflammati... | Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria | [
{
"description": "Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patien... | [
{
"design_group_description": "Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in... | [
"Hyperoxaluria"
] | [
"Mayo Clinic"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "氯沙坦钾",
"lang": "CN"
},
{
"name": "Losartan Potassium",
"lang": "EN"
},
{
"name": "ロサルタンカリウム",
"lang": "JP"
}
]
] | null |
NCT02670330 | [
{
"id_field": "org_study_id",
"id_value": [
"SD-006"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-005679-96"
]
}
] | https://clinicaltrials.gov/study/NCT02670330 | Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa | The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB). | An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa™ (SD-101-6.0) in Patients With Epidermolysis Bullosa | [
{
"description": "SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.",
"name": "SD-101-6.0 cream",
"normalized_type": "3d1aa88261d64c0384137239... | [
{
"design_group_description": "All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.",
"design_group_title": "Experimental: SD-101-6.0 cream",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "7... | [
"Epidermolysis Bullosa"
] | [
"Scioderm, Inc."
] | [
"Amicus Therapeutics, Inc."
] | [
[
{
"name": "尿囊素",
"lang": "CN"
},
{
"name": "Allantoin",
"lang": "EN"
}
]
] | null |
NCT00672373 | [
{
"id_field": "org_study_id",
"id_value": [
"EGB-ZWF-01"
]
},
{
"id_field": "secondary_id",
"id_value": [
"BJHLG-20061B0501900035"
]
},
{
"id_field": "acronym",
"id_value": [
"EGBTD"
]
}
] | https://clinicaltrials.gov/study/NCT00672373 | Extract of Ginkgo Biloba and Tardive Dyskinesia | The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia | A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia | [
{
"description": "EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.",
"name": "Extract of Ginkgo Biloba (EGb-761 capsules)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"YiKangNing"
],
... | [
{
"design_group_description": "Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"... | [
"Tardive Dyskinesia",
"Schizophrenia"
] | [
"Beijing HuiLongGuan Hospital"
] | [
"Peking University"
] | [
[
{
"name": "银杏叶",
"lang": "CN"
},
{
"name": "Ginkgo Biloba leaves Extract",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EGBTD"
}
] |
NCT00321464 | [
{
"id_field": "org_study_id",
"id_value": [
"20050136"
]
}
] | https://clinicaltrials.gov/study/NCT00321464 | A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. | The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer. | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer | [
{
"description": "Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes",
"name": "Denosumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Q4W 4 mg zoledronic acid IV over minimum 15 mi... | [
{
"design_group_title": "zoledronic acid",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo ... | [
"Bone Metastases"
] | [
"Amgen, Inc."
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "地舒单抗",
"lang": "CN"
},
{
"name": "Denosumab",
"lang": "EN"
},
{
"name": "デノスマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "82ed02d83e8e4e2da4e8a8a982504095",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e8ed482eed09882deee5aeee292a92e9",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Stu... |
NCT01864915 | [
{
"id_field": "org_study_id",
"id_value": [
"DMED 1578-13 HOOKEY"
]
},
{
"id_domain": "Health Canada TPD",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"9427-D2773-21C"
]
}
] | https://clinicaltrials.gov/study/NCT01864915 | Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule | Colon capsule endoscopy is a new technology that is a noninvasive method of examining the large bowel. The bowel preparation required for this test differs from colonoscopy in that it needs to clean the colon but also needs to provide propulsion. Most published studies have used medications as part of their regime that... | Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule | [
{
"description": "Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)",
"name": "Prucalopride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"RESTORAN"
],
"type": "... | [
{
"design_group_description": "low dose prucalopride booster arm",
"design_group_title": "No Booster-low dose prucalopride booster",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descrip... | [
"Bowel Cleansing",
"Colon Capsule Completion Times"
] | [
"Queen's University"
] | [
"Religious Hospitallers of St. Joseph of Cornwall Ontario",
"Janssen, Inc."
] | [
[
{
"name": "琥珀酸普芦卡必利",
"lang": "CN"
},
{
"name": "Prucalopride Succinate",
"lang": "EN"
}
]
] | null |
NCT00397839 | [
{
"id_field": "org_study_id",
"id_value": [
"BON105960"
]
},
{
"id_field": "acronym",
"id_value": [
"STRONG"
]
}
] | https://clinicaltrials.gov/study/NCT00397839 | The Effect Of Oral Ibandronate In Male Osteoporosis | Male osteoporosis is a common and important clinical problem, associated with significant morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are osteoporotic. The proposed study will evaluate efficacy and safety of oral ibandronate given 150 mg once-monthly for 12 months versus placebo... | A Parallel, Placebo-controlled, Randomized (2:1) Double-blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-monthly Versus Placebo on LS BMD in Men With Osteoporosis | [
{
"description": "Ibandronate orally (tablet) at a dose of 150 mg once per month",
"name": "Ibandronate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo orally (tablet) at a dose of 150 mg once per month",
"name": "placebo",
"normal... | [
{
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Placebo orally (tablet) at a dose of 150 mg once per month",
"intervention_name"... | [
"Male Osteoporosis"
] | [
"Hoffmann-La Roche, Inc."
] | [
"GSK Plc"
] | [
[
{
"name": "伊班膦酸钠",
"lang": "CN"
},
{
"name": "Ibandronate Sodium",
"lang": "EN"
},
{
"name": "イバンドロン酸ナトリウム水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "d88222205993e8e9208e8e59d8aa494e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "STRONG"
}
] |
NCT06517173 | [
{
"id_field": "org_study_id",
"id_value": [
"Y-3-LC-04"
]
},
{
"id_field": "acronym",
"id_value": [
"NUWA-Y3"
]
}
] | https://clinicaltrials.gov/study/NCT06517173 | Y-3 for Injection in the Treatment of Acute Ischemic Stroke | This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Y-3 in Chinese Subjects with Acute Ischemic Stroke | [
{
"description": "Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.",
"name": "Y-3 for injection",
"normalized_type": "3d1aa88261d64c03841372... | [
{
"design_group_description": "The special solvent Y-3 for injection was extracted with a sterile syringe and injected into a Y-3 lyophilized powder vial for injection. The vial was artificially vibrated until the powder was completely dissolved, and then injected into 250mL 0.9% sodium chloride injection with ... | [
"Acute Ischemic Stroke"
] | [
"Beijing Tiantan Hospital"
] | [
"Neurodawn Pharmaceutical Co., Ltd."
] | [
[
{
"name": "洛贝米柳",
"lang": "CN"
},
{
"name": "Y-3(Neurodawn)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NUWA-Y3"
},
{
"identifier_source": [
{
"code": "394e9950502ae884923588230aa829a4",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],... |
NCT05355337 | [
{
"id_field": "org_study_id",
"id_value": [
"2021-06876-01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2022-001563-26"
]
},
{
"id_field": "acronym",
"id_value": [
"PRIME-PRAXOL"
]
}
] | https://clinicaltrials.gov/study/NCT05355337 | Pramipexole for Anhedonic Depression | The heterogeneity of depression suggests that several different neurocircuits and pathophysiological mechanisms are involved. Anhedonia - the inability to experience pleasure from, or the lack of motivation to carry out, usually enjoyable activities - is a promising endophenotype within the depression spectrum, with a ... | Adjunctive Treatment With Pramipexole for Anhedonic Depression Symptoms in Depression - PRIME-PRAXOL | [
{
"description": "9 weeks of treatment with Pramipexole",
"name": "Pramipexole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "9 weeks of treatment with Placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Pramipexole prolonged-release tablet, 0.26 mg base to 3.15 mg base / day for 9 weeks (individually varying dose titrating during these weeks).",
"design_group_title": "Pramipexole",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f... | [
"Psychiatric Disorders Mood",
"Anhedonia",
"Depression"
] | [
"Region Skåne Holding AB"
] | [
"University of Lund"
] | [
[
{
"name": "盐酸普拉克索",
"lang": "CN"
},
{
"name": "Pramipexole Dihydrochloride",
"lang": "EN"
},
{
"name": "プラミペキソール塩酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PRIME-PRAXOL"
}
] |
NCT01085266 | [
{
"id_field": "org_study_id",
"id_value": [
"DIM20EXT"
]
},
{
"id_field": "acronym",
"id_value": [
"HORIZON PLUS"
]
}
] | https://clinicaltrials.gov/study/NCT01085266 | An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease. | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | [
{
"name": "Dimebon (latrepirdine)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.",
"design_group_title": "Dimebon (latrepirdine)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Huntington Disease"
] | [
"MediVation, Inc."
] | [
"Pfizer Inc."
] | [
[
{
"name": "盐酸地美波林",
"lang": "CN"
},
{
"name": "Dimebolin hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "HORIZON PLUS"
}
] |
NCT03403712 | [
{
"id_field": "org_study_id",
"id_value": [
"NEPA-17-05"
]
}
] | https://clinicaltrials.gov/study/NCT03403712 | A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer | Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion [test] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination [control]; each administ... | A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo®) for the Pr... | [
{
"description": "intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination",
"name": "fosnetupitant/ palonosetron",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"IV NEPA FDC"
],
"type": "Drug"
},
{
"description": "oral netupitant... | [
{
"design_group_description": "intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.<br/>Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)",
"design_group_title": "Test group",
... | [
"Chemotherapy-induced Nausea and Vomiting"
] | [
"Helsinn Healthcare SA"
] | [
"Physicians' Services, Inc. Foundation",
"Emerald Clinical Trials Pty Ltd."
] | [
[
{
"name": "地塞米松磷酸钠",
"lang": "CN"
},
{
"name": "Dexamethasone Sodium Phosphate",
"lang": "EN"
},
{
"name": "デキサメタゾンリン酸エステルナトリウム",
"lang": "JP"
}
],
[
{
"name": "奈妥匹坦帕洛诺司琼",
"lang": "CN"
},
{
"name": "Netupitant/Palonoset... | null |
NCT00312195 | [
{
"id_field": "org_study_id",
"id_value": [
"BUP3201"
]
}
] | https://clinicaltrials.gov/study/NCT00312195 | Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain | The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal system in subjects with chronic nonmalignant pain syndromes currently controlled by oral opioids. The double-blind treatment intervention ... | An Open-label Run-in, Followed by a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Show the Effectiveness of Buprenorphine Transdermal System in Management of Patients With Chronic Nonmalignant Pain Syndromes | [
{
"description": "Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.",
"name": "Buprenorphine transdermal patch",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Butrans™"
],
"type": "Drug"
},
{
"description": "Placebo to match bup... | [
{
"design_group_description": "Buprenorphine transdermal patch",
"design_group_title": "BTDS (5, 10 or 20)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Buprenorphine tr... | [
"Chronic Non-malignant Pain"
] | [
"Purdue Pharma LP"
] | [
"Napp Pharmaceuticals Ltd."
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine",
"lang": "EN"
... | null |
NCT03496298 | [
{
"id_field": "org_study_id",
"id_value": [
"EFC14828"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2017-002954-35"
]
},
{
"id_domain": "UTN",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
... | https://clinicaltrials.gov/study/NCT03496298 | Effect of Efpeglenatide on Cardiovascular Outcomes | Primary Objective:<br/>To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk.<br/>Secondary Objectives:<br/>To demonstrate that efpeglenatide 4 and 6 mg was superior to place... | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | [
{
"description": "Pharmaceutical form: Solution for injection,<br/>Route of administration: SC",
"name": "Efpeglenatide (SAR439977)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Pharmaceutical form: Solution for injection<br/>Route of administra... | [
{
"design_group_description": "Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ec... | [
"Type 2 Diabetes Mellitus"
] | [
"Sanofi"
] | [
"Hanmi Pharmaceutical Co., Ltd."
] | [
[
{
"name": "Efpeglenatide",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "0e929ed5a2dd84d23ae4d39ead938d2a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "32e802950259e242d222aa28a24a5545",
"s... |
NCT03062839 | [
{
"id_field": "org_study_id",
"id_value": [
"TDAHMEL"
]
}
] | https://clinicaltrials.gov/study/NCT03062839 | Melatonin as Adjuvant Treatment for ADHD in Adults | This study aims to evaluate the effect of melatonin supplementation as adjuvant treatment in ADHD in adults. | Melatonin as Adjuvant Treatment for ADHD in Adults | [
{
"description": "Melatonin 5 mg taken 30 minutes before bed time",
"name": "Melatonin 5 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Melatonina"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Melatonin 5 mg taken 30 minutes before bed time",
"design_group_title": "Melatonin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Melatonin... | [
"Attention Deficit Hyperactivity Disorder"
] | [
"Hospital Israelita Albert Einstein"
] | [
"Fundação de Amparo à Pesquisa do Estado de São Paulo",
"University of Sao Paulo"
] | [
[
{
"name": "褪黑素",
"lang": "CN"
},
{
"name": "Melatonin",
"lang": "EN"
},
{
"name": "メラトニン",
"lang": "JP"
}
]
] | null |
NCT00641056 | [
{
"id_field": "org_study_id",
"id_value": [
"H8O-MC-GWBR (DURATION - 3)"
]
}
] | https://clinicaltrials.gov/study/NCT00641056 | Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) | The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability. | Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea | [
{
"description": "subcutaneous injection, 2.0mcg, once weekly",
"name": "Exenatide Once Weekly",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "subcutaneous injection, variable dose, QD",
"name": "Insulin Glargine",
"normalized_type": "3d1a... | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "subcutaneous injection, 2.0mcg, once weekly",
"intervention_name": "Exenatide Once Weekly",
... | [
"Type 2 Diabetes Mellitus"
] | [
"AstraZeneca PLC"
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "艾塞那肽",
"lang": "CN"
},
{
"name": "Exenatide",
"lang": "EN"
},
{
"name": "エキセナチド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "4ad2322a380e95aded9852e5202d42a2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e5d92ad59a2825eea525dea538232222",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DUR... |
NCT00548548 | [
{
"id_field": "org_study_id",
"id_value": [
"AVF4200g"
]
},
{
"id_domain": "Hoffmann-La Roche",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"BO20904"
]
},
{
"id_field": "acronym",
"id_value": [
"AVAGAST"
]
}
] | https://clinicaltrials.gov/study/NCT00548548 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer | This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or metastatic gastric cancer who had not received prior chemotherapy for advanced or metastatic disease... | A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer | [
{
"description": "Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.",
"name": "Bevacizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral capecitabine 1,000 mg/m˄2 twice daily for... | [
{
"design_group_description": "Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cispl... | [
"Adenocarcinoma"
] | [
"Genentech, Inc."
] | [
"Chugai Pharmaceutical Co., Ltd.",
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "ベバ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "28283dd39ae23a4282d5e93d59a58e58",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "5da2922d29889e858008932a24432088",
"s... |
NCT01660893 | [
{
"id_field": "org_study_id",
"id_value": [
"SR 3-01"
]
}
] | https://clinicaltrials.gov/study/NCT01660893 | Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth | The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and Placebo for inducing pulpal anesthesia of the maxillary teeth in adults. | A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults | [
{
"description": "3 unilateral intranasal sprays per dose",
"name": "Tetracaine HCl 3% and oxymetazoline HCl 0.05%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Kovacaine Mist"
],
"type": "Drug"
},
{
"description": "3 unilateral intranasal sprays per... | [
{
"design_group_description": "Tetracaine HCl 3% and oxymetazoline HCl 0.05%",
"design_group_title": "Kovacaine Mist, 3 sprays unilateral",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_... | [
"Anesthesia"
] | [
"St. Renatus LLC"
] | [
"Triligent International",
"Rho, Inc."
] | [
[
{
"name": "盐酸羟甲唑啉",
"lang": "CN"
},
{
"name": "Oxymetazoline Hydrochloride",
"lang": "EN"
},
{
"name": "オキシメタゾリン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸丁卡因",
"lang": "CN"
},
{
"name": "Tetracaine Hydrochloride",
"la... | null |
NCT00003824 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000066978"
]
},
{
"id_domain": "SWOG",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"S9809"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value"... | https://clinicaltrials.gov/study/NCT00003824 | S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer.<br/>PURPOSE: Randomized ph... | The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder | [
{
"description": "500 mg oral bid for 3 days starting the night before resection",
"name": "cephalexin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"antibiotic"
],
"type": "Drug"
},
{
"name": "surgical procedure",
"normalized_type": "a49da0f51674... | [
{
"design_group_description": "ciprofloxacin",
"design_group_title": "cipro",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "500 mg oral bid for 3 days starting the night b... | [
"Bladder Cancer"
] | [
"SWOG"
] | [
"National Cancer Institute"
] | [
[
{
"name": "头孢氨苄",
"lang": "CN"
},
{
"name": "Cephalexin",
"lang": "EN"
},
{
"name": "セファレキシン",
"lang": "JP"
}
],
[
{
"name": "环丙沙星",
"lang": "CN"
},
{
"name": "Ciprofloxacin",
"lang": "EN"
},
{
"name"... | null |
NCT01885559 | [
{
"id_field": "org_study_id",
"id_value": [
"HALT PKD B"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01DK062401"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01D... | https://clinicaltrials.gov/study/NCT01885559 | HALT Progression of Polycystic Kidney Disease Study B | The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two simultaneous multicenter randomized clinical trials targeting different levels of kidney function... | HALT Progression of Polycystic Kidney Disease Study B | [
{
"description": "Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.",
"name": "Lisinopril",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ACE",
"ACE-I",
"Ace-Inhibitor... | [
{
"design_group_description": "Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg",
"design_group_title": "ACE-I + placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [... | [
"Kidney, Polycystic"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
"Merck Sharp & Dohme Corp.",
"Washington University School of Medicine",
"Boehringer Ingelheim GmbH",
"University of Pittsburgh",
"The Polycystic Kidney Disease Research Foundation"
] | [
[
{
"name": "赖诺普利",
"lang": "CN"
},
{
"name": "Lisinopril",
"lang": "EN"
},
{
"name": "リシノプリル水和物",
"lang": "JP"
}
],
[
{
"name": "替米沙坦",
"lang": "CN"
},
{
"name": "Telmisartan",
"lang": "EN"
},
{
"name"... | [
{
"identifier_source": [
{
"code": "5a08eea99222a0e49e88e543229822e5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8a2852828aa2a9582da045585ea0e82e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "HAL... |
NCT00729794 | [
{
"id_field": "org_study_id",
"id_value": [
"VSE-226-2008"
]
},
{
"id_field": "acronym",
"id_value": [
"VSE-2"
]
}
] | https://clinicaltrials.gov/study/NCT00729794 | Vasopressin, Epinephrine, and Steroids for Cardiac Arrest | The simultaneous activation of adrenergic and vasopressin receptors, in conjunction with a potential steroid-mediated enhancement of the vascular reactivity to epinephrine may have beneficial effects in patients with cardiac arrest. This hypothesis is supported by the single-center results of NCT 00411879. The investig... | Vasopressin, Epinephrine, and Corticosteroids for Inhospital Cardiac Arrest: A Multicenter Randomized Controlled Trial | [
{
"description": "Combination Treatment<br/>Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR",
"name": "Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"typ... | [
{
"design_group_description": "Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.",
"design_group_title": "Study Group",
"design_group_typ... | [
"Cardiac Arrest"
] | [
"National & Kapodistrian University of Athens"
] | [
"University of Thessaly"
] | [
[
{
"name": "重酒石酸肾上腺素",
"lang": "CN"
},
{
"name": "Epinephrine Bitartrate",
"lang": "EN"
}
],
[
{
"name": "甲泼尼龙",
"lang": "CN"
},
{
"name": "Methylprednisolone",
"lang": "EN"
},
{
"name": "メチルプレドニゾロン",
"lang": "JP"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "VSE-2"
}
] |
NCT03464019 | [
{
"id_field": "org_study_id",
"id_value": [
"MSP-2017-1138"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-000308-41"
]
},
{
"id_field": "acronym",
"id_value": [
"NODE-301"
]
}
] | https://clinicaltrials.gov/study/NCT03464019 | Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). | This was a three-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil nasal spray (NS) self-administered by participants who experienced an episode of paroxysmal supraventricular tachycardia (PSVT) in an at-home setting.<br/>NODE-301 Part 1 included par... | Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 and RAPID Studies | [
{
"description": "Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.",
"name": "Etripamil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_na... | [
{
"design_group_description": "Self-administration of a single dose etripamil 70 mg for a perceived episode of PSVT.",
"design_group_title": "Part 1: Etripamil 70 mg Single Dose",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interve... | [
"Paroxysmal Supraventricular Tachycardia"
] | [
"Milestone Pharmaceuticals, Inc."
] | [
"IQVIA Biotech LLC",
"Medpace, Inc."
] | [
[
{
"name": "艾曲帕米",
"lang": "CN"
},
{
"name": "Etripamil",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2e0e50e85ae5d223935e335dd9ad9958",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "3a982e84a899ee3222e5ea5e2ed08232",
"s... |
NCT00980876 | [
{
"id_field": "org_study_id",
"id_value": [
"STPh 09/08"
]
}
] | https://clinicaltrials.gov/study/NCT00980876 | A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension | The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa. | Multicentric, Double Blind, Randomized, Parallel Comparative Study Between Ciprofloxacin HCl 2 mg/mL + Hydrocortisone 10 mg/mL Ear Suspension and Cipro HC®, for the Assessment of Efficacy and Safety in Patients With Otitis Externa. | [
{
"description": "Cipro HC (Ciprofloxacin HCl and Hydrocortisone)",
"name": "Cipro HC",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Ciprofloxacin Hydrochloride and Hydrocortisone",
"name": "Ciprofloxacin HCl and Hydrocortisone",
"normali... | [
{
"design_group_description": "Reference product",
"design_group_title": "Cipro HC",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Cipro HC (Ciprofloxacin HCl and Hyd... | [
"Otitis Externa"
] | [
"Farmoquímica SA"
] | [
"Pharmagenix Projetos em Medicina Farmacêutica Ltda."
] | [
[
{
"name": "醋酸氢化可的松",
"lang": "CN"
},
{
"name": "Hydrocortisone Acetate",
"lang": "EN"
}
]
] | null |
NCT04372589 | [
{
"id_field": "org_study_id",
"id_value": [
"ATTACC"
]
},
{
"id_domain": "Ozmosis Research Inc",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"OZM-113"
]
},
{
"id_field": "acronym",
"id_value": [
"ATTACC"
]
}
] | https://clinicaltrials.gov/study/NCT04372589 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host inflammatory response and activation of coagulation pathways. Macro- and micro-vascular thrombosis may contribute to morbidity, organ failure, and death. Therapeutic anticoagulation with heparin may improve clinical outcomes in pat... | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) | [
{
"description": "Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dal... | [
{
"design_group_description": "Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low m... | [
"COVID-19",
"Pneumonia"
] | [
"University of Manitoba"
] | [
"University Health Network"
] | [
[
{
"name": "肝素钙",
"lang": "CN"
},
{
"name": "Heparin Calcium",
"lang": "EN"
},
{
"name": "ヘパリンカルシウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "085232ad80e955d4802d2e9eea858242",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ATTACC"
}
] |
NCT01384877 | [
{
"id_field": "org_study_id",
"id_value": [
"H10-00150"
]
}
] | https://clinicaltrials.gov/study/NCT01384877 | Subcutaneous Lidocaine For Cancer-Related Pain | This study's primary objective is to test the hypothesis that a single infusion of subcutaneous lidocaine can cause a clinically useful reduction in cancer pain within 48 hours of infusion and lasting a minimum of 7 days. A clinically useful reduction in pain is defined by either a 2-point reduction (on a 0-10 scale) i... | A Randomized Double Blind Placebo Controlled Crossover Trial of the Use of Subcutaneous Lidocaine Infusion (SCLI) for Chronic Cancer-related Pain | [
{
"description": "10mg/kg by subcutaneous infusion over 5.5 hours",
"name": "Lidocaine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lignocaine",
"Xylocaine"
],
"type": "Drug"
},
{
"description": "Same volume as for lidocaine infusion, identica... | [
{
"design_group_description": "Lidocaine",
"design_group_title": "Lidocaine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "10mg/kg by subcutaneous infusion over 5.5 hours... | [
"Cancer-related Pain"
] | [
"British Columbia Cancer Agency"
] | [
"Bc Cancer Foundation"
] | [
[
{
"name": "利多卡因",
"lang": "CN"
},
{
"name": "Lidocaine",
"lang": "EN"
},
{
"name": "リドカイン",
"lang": "JP"
}
]
] | null |
NCT03928275 | [
{
"id_field": "org_study_id",
"id_value": [
"14549"
]
}
] | https://clinicaltrials.gov/study/NCT03928275 | The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma | The investigators aim to include 100 local participants over the next 5 years in a two-stage sequential randomized interventional study of intralesional Interleukin-2 (IL-2) and Bacillus Calmette Guerin (BCG) to assess the utility of treating cutaneous metastatic melanoma (CMM). | The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma | [
{
"description": "IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.",
"name": "Interleukin-2",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Proleukin (Aldesleukin)"
],
... | [
{
"design_group_description": "CMM patients will received 4 treatments of intralesional Interleukin-2 two weeks apart over an eight week period.",
"design_group_title": "Intralesional IL-2 Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf... | [
"Cutaneous Metastatic Melanoma"
] | [
"Nova Scotia Health Authority"
] | [
"Nova Scotia Health Authority"
] | [
[
{
"name": "卡介苗(Organon)",
"lang": "CN"
},
{
"name": "BCG Live(Organon & Co.)",
"lang": "EN"
}
],
[
{
"name": "阿地白介素",
"lang": "CN"
},
{
"name": "Aldesleukin",
"lang": "EN"
}
]
] | null |
NCT05519683 | [
{
"id_field": "org_study_id",
"id_value": [
"HUM00217301"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5UH3NS115108-04"
]
},
{
"id_field": "acronym",
"id_value": [
"Home-TEA"
]
}
] | https://clinicaltrials.gov/study/NCT05519683 | Home Transcutaneous Electrical Acustimulation (TEA) | This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain. | Effects of Home-based TEA for Abdominal Pain in Patients With Irritable Bowel Syndrome (IBS) | [
{
"description": "The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.",
"name": "... | [
{
"design_group_description": "The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are ... | [
"Irritable Bowel Syndrome With Constipation"
] | [
"University of Michigan"
] | [
"National Institute of Neurological Disorders & Stroke",
"National Center For Complementary & Integrative Health"
] | [
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Home-TEA"
}
] |
NCT00284258 | [
{
"id_field": "org_study_id",
"id_value": [
"01023010 / TOP-003"
]
}
] | https://clinicaltrials.gov/study/NCT00284258 | Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer | This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI. | Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer | [
{
"description": "TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.",
"name": "CPT-11 and TS-1",
"normalized_type": "3d1aa88261d64c0384137... | [
{
"design_group_description": "CPT-11 and TS-1",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "TS-1 was administered orally at 40-60 mg twice da... | [
"Colorectal Cancer"
] | [
"Taiho Pharmaceutical Co., Ltd."
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "替吉奥",
"lang": "CN"
},
{
"name": "Tegafur/Gimeracil/Oteracil Potassium",
"lang": "EN"
},
{
"name": "テガフール/ギメラシル/オテラシルカリウム",
"lang": "JP"
}
],
[
{
"name": "盐酸伊立替康",
"lang": "CN"
},
{
"name": "Irinotecan Hydrochl... | [
{
"identifier_source": [
{
"code": "ae9892eaeaa202dedae4aa34258e0222",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "FIRIS"
},
{
"identifier_source": [
{
"code": "e290d94a95532a502e2ea22e54a52ea8",
"source": "CT_RESULT_AUT... |
NCT02029352 | [
{
"id_field": "org_study_id",
"id_value": [
"NL47392.068.13"
]
}
] | https://clinicaltrials.gov/study/NCT02029352 | Topical Green Tea Ointment in Treatment of Superficial Skin Cancer | Basal cell carcinoma (BCC) is the most frequently occurring nonmelanoma skin cancer in Caucasians, representing approximately 80% of cases. Incidence rates for men and women in the Netherlands are 165 and 157 per 100,000 person-years respectively and are still rising 3-10% annually. In 2009, the lifetime risk for devel... | Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial. | [
{
"name": "Sinecatechins 10%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Veregen"
],
"type": "Drug"
},
{
"description": "Composition, apart from the active substance, is otherwise identical to the investigational medical product.",
"name": "Placebo... | [
{
"design_group_description": "Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointm... | [
"Carcinoma, Basal Cell"
] | [
"Maastricht UMC+"
] | [
"Will-Pharma NV",
"MediGene AG"
] | [
[
{
"name": "赛儿茶素",
"lang": "CN"
},
{
"name": "Sinecatechins",
"lang": "EN"
}
]
] | null |
NCT04368728 | [
{
"id_field": "org_study_id",
"id_value": [
"C4591001"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2020-002641-42"
]
}
] | https://clinicaltrials.gov/study/NCT04368728 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.<br/>The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.<br/>The ... | A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS | [
{
"description": "Intramuscular injection",
"name": "BNT162b1",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Intramuscular injection",
"name": "BNT162b2",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biologica... | [
{
"design_group_title": "10 µg dose, 18-55 years of age (2 doses)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intramuscular injection",
"intervention_name": "BNT16... | [
"SARS-CoV-2 Infection",
"COVID-19"
] | [
"BioNTech SE"
] | [
"Pfizer Inc."
] | [
[
{
"name": "复必泰",
"lang": "CN"
},
{
"name": "Comirnaty-COVID-19 mRNA vaccine",
"lang": "EN"
},
{
"name": "トジナメラン",
"lang": "JP"
}
],
[
{
"name": "BNT-161b1",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "32aa9d2d9a8e2aa449a22888852a2358",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "C4591001"
}
] |
NCT04292314 | [
{
"id_field": "org_study_id",
"id_value": [
"TQ/Omega-3 on Thalassemia"
]
}
] | https://clinicaltrials.gov/study/NCT04292314 | Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia | The aim of the present study is evaluating the strength of combination therapy of hydroxy urea, omega 3, nigella sativa and honey on antioxidant-oxidant status (OXIDATIVE STRESS) in response to reactive oxygen species production (LIPID PEROXIDATION) and their effect on iron intoxication (IRON CHELATION) in pediatric ma... | Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia | [
{
"description": "Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months",
"name": "Omega 3",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Nigella sativa supplementation (1g black seed oil contain... | [
{
"design_group_description": "50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.<br/>in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/defe... | [
"Iron Overload",
"Oxidative Stress",
"Thalassemia Major"
] | [
"Beni-Suef University"
] | [
"University of Arizona"
] | [
[
{
"name": "ω-3酸乙酯(Trygg Pharma AS)",
"lang": "CN"
},
{
"name": "Omega-3-acid ethyl esters(Trygg Pharma AS)",
"lang": "EN"
}
],
[
{
"name": "甲磺酸去铁胺",
"lang": "CN"
},
{
"name": "Deferoxamine Mesylate",
"lang": "EN"
},
{
"n... | null |
NCT03440359 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB 12-07-FB-0170"
]
}
] | https://clinicaltrials.gov/study/NCT03440359 | Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole | Aromatase inhibitors such as letrozole are hypothesized to maintain normal hypothalamic/ pituitary feedback mechanisms and in the case of OI (ovulation induction) in women with PCOS, may act to increase follicular sensitivity to FSH by increasing intrafollicular androgen levels. Letrozole also may act to increase midlu... | "Supplementation of the Luteal Phase With Vaginal Progesterone (Crinone 8%) in Women With Polycystic Ovary Syndrome Undergoing Ovulation Induction With Letrozole: A Prospective and Randomized Controlled Trial | [
{
"description": "progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.",
"name": "Progesterone Vaginal Gel 8%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase",
"... | [
"Polycystic Ovary Syndrome"
] | [
"Eastern Virginia Medical School"
] | [
"Actavis, Inc."
] | [
[
{
"name": "来曲唑",
"lang": "CN"
},
{
"name": "Letrozole",
"lang": "EN"
},
{
"name": "レトロゾール",
"lang": "JP"
}
],
[
{
"name": "黄体酮",
"lang": "CN"
},
{
"name": "Progesterone",
"lang": "EN"
},
{
"name": "プロ... | null |
NCT01203852 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB201700661-N"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01GM074492-06"
]
},
{
"id_field": "acronym",
"id_value": [
"PEAR2"
]
}
] | https://clinicaltrials.gov/study/NCT01203852 | Pharmacogenomic Evaluation of Antihypertensive Responses 2 | There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences b... | Pharmacogenomic Evaluation of Antihypertensive Responses 2 | [
{
"description": "Metoprolol 50 mg twice daily titrated to 100 mg twice daily<br/>Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.",
... | [
{
"design_group_description": "Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additi... | [
"Hypertension"
] | [
"University of Florida"
] | [
"National Institute of General Medical Sciences"
] | [
[
{
"name": "琥珀酸美托洛尔",
"lang": "CN"
},
{
"name": "Metoprolol Succinate",
"lang": "EN"
}
],
[
{
"name": "氯噻酮",
"lang": "CN"
},
{
"name": "Chlorthalidone",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2d9e2328ea85a28542a33e20842e8a22",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PEAR2"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.